[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 24319
1. Zhang MZ, Sun ZC, Fu XR, Nan FF, Fan QX, Wu XA, Geng L, Ma W, Wang RL: Analysis of serum proteome profiles of non-Hodgkin lymphoma for biomarker identification. J Proteomics; 2009 Aug 20;72(6):952-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of serum proteome profiles of non-Hodgkin lymphoma for biomarker identification.
  • Serum samples from non-Hodgkin lymphoma (NHL) patients who had not undergone chemotherapy, lymphnoditis patients, and healthy adults were analyzed using surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) to detect the differentially expressed serum proteins.
  • A protein with the m/z of M10 197.91 u was expressed at a significantly higher level in the NHL group, compared to the other groups.
  • Furthermore, differences were also significant among different stages of NHL and among samples with different International Prognosis Index (IPI) scores or lactase dehydrogenase (LDH) levels.
  • The three identified proteins may offer a new serological approach for early diagnosis, differential diagnosis, and pathogenic investigation of NHL.
  • And the protein with the m/z of M10 197.91 u may be a new serological biomarker for monitoring treatment response and evaluating the prognosis of patients with NHL.
  • [MeSH-major] Blood Proteins / chemistry. Lymphoma, Non-Hodgkin / blood. Proteomics / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361584.001).
  • [ISSN] 1876-7737
  • [Journal-full-title] Journal of proteomics
  • [ISO-abbreviation] J Proteomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Proteins; 0 / Proteome; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Poplar S, Allford S, Rooney N: Chronic parvovirus B19 infection leading to red cell aplasia following treatment of Hodgkin lymphoma. Br J Haematol; 2010 Mar;148(5):671
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic parvovirus B19 infection leading to red cell aplasia following treatment of Hodgkin lymphoma.
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Chronic Disease. Hodgkin Disease / drug therapy. Humans. Immunocompromised Host. Immunoglobulins, Intravenous / therapeutic use. Male. Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681883.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


3. Schroeder JC: Metabolic susceptibility to agricultural pesticides and non-Hodgkin's lymphoma. Scand J Work Environ Health; 2005;31 Suppl 1:26-32; discussion 5-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic susceptibility to agricultural pesticides and non-Hodgkin's lymphoma.
  • Epidemiologic studies have failed to establish clearly whether agricultural pesticides contribute to the genesis of non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Occupational Exposure. Pesticides / toxicity

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190146.001).
  • [ISSN] 0355-3140
  • [Journal-full-title] Scandinavian journal of work, environment & health
  • [ISO-abbreviation] Scand J Work Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Pesticides; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Number-of-references] 93
  •  go-up   go-down


Advertisement
4. Cheung MC, Hicks LK, Leitch HA: Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk; 2010 Apr;10(2):E22-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
  • Hodgkin lymphoma (HL) is the second most common non-AIDS-defining malignancy among persons infected with HIV, and its incidence might be increasing in the current era of combination antiretroviral therapy (cART).
  • With the immune reconstitution afforded by cART, most patients are now able to tolerate the standard-dose chemotherapies administered to immunocompetent individuals with HL, such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine).
  • The implications for the treatment of patients with HL in the current era of cART are discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease. Lymphoma, AIDS-Related


5. Kubota Y, Waki M: [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia]. Rinsho Ketsueki; 2009 Mar;50(3):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].
  • A 45-year-old woman was diagnosed with essential thrombocythemia (ET) in August 1987 and received treatment with alkylating agents (total administration dose, busulfan 378 mg, MCNU 700 mg) because of a history of myocardial infarction.
  • Swelling of a large paraaortic lymph node of 6 cm in diameter was detected by CT scan.
  • Lymph node biopsy revealed diffuse large B-cell lymphoma.
  • Lymphoma cells were positive for CD10, CD19, CD20 and kappa-chain.
  • The clinical stage was I.
  • Non-Hodgkin lymphoma secondary to ET is a rare event.
  • Such cases should therefore be accumulated to evaluate the mechanism of onset and clinical characteristics of lymphoma secondary to ET.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Thrombocythemia, Essential / complications. Thrombocythemia, Essential / drug therapy

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352088.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Nitrosourea Compounds; 4F4X42SYQ6 / Rituximab; G1LN9045DK / Busulfan; RYH2T97J77 / ranimustine
  •  go-up   go-down


6. He Y, Xiao R, Ji X, Li L, Chen L, Xiong J, Xiao W, Wang Y, Zhang L, Zhou R, Tan X, Bi Y, Jiang YP, Jin Y, Tan J: EBV promotes human CD8 NKT cell development. PLoS Pathog; 2010 May;6(5):e1000915
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we have studied total 177 eligible patients and subjects including 128 healthy latent Epstein-Barr-virus(EBV)-infected subjects, 17 newly-onset acute infectious mononucleosis patients, 16 newly-diagnosed EBV-associated Hodgkin lymphoma patients, and 16 EBV-negative normal control subjects.
  • We here show that the average frequency of total and CD8(+) NKT cells in PBMCs from 128 healthy latent EBV-infected subjects is significantly higher than in 17 acute EBV infectious mononucleosis patients, 16 EBV-associated Hodgkin lymphoma patients, and 16 EBV-negative normal control subjects.
  • Thus, upon interaction with certain viruses, CD8 lineage-specific NKT cells are developed, differentiated and matured intrathymically, a finding with potential therapeutic importance against viral infections and tumors.
  • [MeSH-minor] Animals. Cell Differentiation / immunology. Cell Lineage / immunology. Cells, Cultured. Chimera. Female. Flow Cytometry. Gene Expression / immunology. Hodgkin Disease / immunology. Humans. Interferon-gamma / metabolism. Interleukin-7 / genetics. Mice. Mice, SCID. Organ Culture Techniques. Perforin. Pore Forming Cytotoxic Proteins / metabolism. Thymus Gland / immunology. Thymus Gland / virology

  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Mar 25;263(5154):1774-8 [7907820.001]
  • [Cites] J Exp Med. 2003 Apr 21;197(8):1051-7 [12695492.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):2009-15 [10657652.001]
  • [Cites] J Exp Med. 2000 Mar 6;191(5):771-80 [10704459.001]
  • [Cites] Eur J Immunol. 2000 Jun;30(6):1544-50 [10898489.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):61-72 [11150537.001]
  • [Cites] J Exp Med. 2001 May 21;193(10):1221-6 [11369793.001]
  • [Cites] Nat Immunol. 2001 Oct;2(10):971-8 [11550008.001]
  • [Cites] J Virol. 2001 Nov;75(22):10746-54 [11602716.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1490-5 [11801694.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):625-36 [11877485.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):637-41 [11877486.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3140-4 [11907064.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):835-44 [11927628.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):869-79 [11927631.001]
  • [Cites] J Exp Med. 2002 Apr 1;195(7):893-905 [11927633.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5514-20 [12023346.001]
  • [Cites] J Virol. 2002 Aug;76(15):7528-34 [12097565.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2397-406 [12193707.001]
  • [Cites] Nat Immunol. 2002 Sep;3(9):867-74 [12154358.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):966-74 [12244311.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):5338-46 [12391255.001]
  • [Cites] Immunology. 2003 Jan;108(1):3-9 [12519296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2663-8 [12598649.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):164-9 [12634786.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):907-18 [12682110.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):231-7 [15039760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):7058-63 [15118099.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7350-8 [15187111.001]
  • [Cites] Blood. 1988 Oct;72(4):1117-23 [3167199.001]
  • [Cites] J Exp Med. 1991 Apr 1;173(4):971-80 [1706754.001]
  • [Cites] J Exp Med. 1992 Sep 1;176(3):845-53 [1512547.001]
  • [Cites] J Immunol. 1995 Feb 1;154(3):1440-9 [7822809.001]
  • [Cites] Annu Rev Immunol. 1997;15:405-31 [9143694.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6410-9 [10352254.001]
  • [Cites] J Clin Invest. 2004 Nov;114(10):1379-88 [15545985.001]
  • [Cites] Science. 2004 Dec 3;306(5702):1786-9 [15539565.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4150-6 [15328159.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):879-89 [15724241.001]
  • [Cites] Nat Med. 2005 Mar;11(3):340-5 [15711562.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):695-701 [15738056.001]
  • [Cites] Annu Rev Immunol. 2005;23:877-900 [15771592.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1230-7 [14578883.001]
  • [Cites] J Immunol Methods. 2004 Feb 15;285(2):197-214 [14980434.001]
  • [Cites] Annu Rev Immunol. 2004;22:817-90 [15032598.001]
  • [Cites] Nature. 2005 Mar 24;434(7032):520-5 [15791257.001]
  • [Cites] Nature. 2005 Mar 24;434(7032):525-9 [15791258.001]
  • [Cites] PLoS Biol. 2005 Apr;3(4):e113 [15799695.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1399-407 [15816002.001]
  • [Cites] Virology. 2005 Jul 5;337(2):242-52 [15916790.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1692-701 [15915536.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):4914-26 [16210593.001]
  • [Cites] Eur J Immunol. 2006 Feb;36(2):278-86 [16385629.001]
  • [Cites] Blood. 2006 Jul 15;108(2):487-92 [16410443.001]
  • [Cites] Nat Immunol. 2006 Sep;7(9):978-86 [16921381.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1316-22 [17057712.001]
  • [Cites] Annu Rev Immunol. 2007;25:297-336 [17150027.001]
  • [Cites] Nat Rev Immunol. 2007 Jul;7(7):505-18 [17589542.001]
  • [Cites] Nature. 2007 Jul 5;448(7149):44-9 [17581592.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1420-7 [17991806.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4415-24 [18354162.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7276-86 [18490727.001]
  • [Cites] Nat Rev Immunol. 2008 Oct;8(10):788-801 [18802443.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3208-15 [19666871.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):7935-44 [19808969.001]
  • [RetractionIn] PLoS Pathog. 2010;6(12). doi: 10.1371/annotation/1730f52d-2ba9-4f08-b330-47d71b31ae4a [21151944.001]
  • (PMID = 20502687.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL7 protein, human; 0 / Interleukin-7; 0 / PRF1 protein, human; 0 / Pore Forming Cytotoxic Proteins; 126465-35-8 / Perforin; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2873918
  •  go-up   go-down


7. Colović N, Cemerikić V, Colović R, Grubor N: [Primary pancreatic non-Hodgkin's lymphoma]. Srp Arh Celok Lek; 2005 May-Jun;133(5-6):276-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pancreatic non-Hodgkin's lymphoma].
  • Diffuse large-cell B lymphoma of the pancreas is a rare disease, representing less than 1% of all non-Hodgkin's lymphomas and less than 0.9% of all malignant tumours of the pancreas.
  • About 150 cases of the disease have been observed so far.
  • They are usually larger (average size of 8 cm) and are non-resectionable.
  • As a rule, exact diagnosis is based on the histology and the immunohistology of the specimen taken during open surgery performed for general diagnosis of the pancreatic tumour.
  • Very rarely can a very reliable and experienced cytopathologist establish a proper diagnosis based on material obtained from a fine needle biopsy.
  • The disease usually responds positively to immunochemotherapy according to protocol R-CHOP.
  • We present two women, 66 and 49 years old, in whom a diagnosis of large-cell B lymphoma of the pancreas was established, based on the histology and the immunohistochemistry of a specimen taken during open surgery performed in order to remove pancreatic tumours, which turned out to be non-resectionable.
  • The authors would like to point out the importance of a proper histological diagnosis, which permitted the application of immunochemotherapy alone or together with additional radiotherapy with at least temporarily favourable results.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16392287.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


8. Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol; 2005 Jul;84(7):462-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Following autologous stem cell transplantation (SCT) for HD, overall survival was 56% [95% confidence interval (CI): 40-72%] with a disease-/progression-free survival of 49%, reaching a plateau at 5 years.
  • Using multivariate Cox regression analysis BEAM conditioning (carmustine, cytarabine, etoposide and melphalan) was predictive for favourable outcome, better disease-/progression-free survival and a significantly lower risk for relapse.
  • Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years.
  • In the multivariate Cox regression analysis stage of disease at time of SCT was the most powerful parameter for overall survival, disease-/progression-free survival and relapse.
  • Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death.
  • Because of the high risk of relapse/progression in both disease categories and the additional high rate of second malignancies in HD patients, allogeneic stem cells should be considered a valuable alternative for selected patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Transplantation, Autologous
  • [MeSH-minor] Adolescent. Adult. Austria. Child. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Recurrence. Registries. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726362.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Prontera P, Escande F, Cocchi G, Donti E, Martini A, Sensi A: An intermediate phenotype between Hay-Wells and Rapp-Hodgkin syndromes in a patient with a novel P63 mutation: confirmation of a variable phenotypic spectrum with a common aetiology. Genet Couns; 2008;19(4):397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intermediate phenotype between Hay-Wells and Rapp-Hodgkin syndromes in a patient with a novel P63 mutation: confirmation of a variable phenotypic spectrum with a common aetiology.
  • The ankyloblepharon-ectodermal defects-cleft lip and palate (Hay-Wells or AEC) and the Rapp-Hodgkin syndrome (RHS) are rare autosomal dominant ectodermal dysplasias due to mutations in the transcription factor gene P63.
  • The two disorders share common features and may represent different phenotypic expressions of the same clinical entity.
  • Molecular heterogeneity cannot account for the clinical heterogeneity, because the same mutations were observed both in patient with RHS and with AEC syndrome.


10. Janz M, Stühmer T, Vassilev LT, Bargou RC: Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia; 2007 Apr;21(4):772-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.
  • The status of the p53 pathway in classical Hodgkin lymphoma (cHL) remains unclear, and a lack of proven TP53 mutations contrasts with often high expression levels of p53 protein.
  • In this study, we demonstrate that pharmacologic activation of the p53 pathway with the murine double minute 2 (MDM2) antagonist nutlin-3 in Hodgkin lymphoma-derived cell lines leads to effective apoptosis induction and sensitizes the cells to other anticancer drugs.
  • Conversely, cells with defects in the HSP90/nuclear factor-kappa B pathway expressing wild-type p53 are more resistant to geldanamycin, but still sensitive to nutlin-3.
  • Our results suggest that selective activation of p53 by MDM2 antagonists as a single agent or in combination with conventional chemotherapeutics and/or inhibitors of p53-independent survival pathways may offer effective treatment options for patients with cHL.
  • Importantly, because nutlins and HSP90 inhibitors are non-genotoxic agents, their use might offer a means to reduce the genotoxic burden of current chemotherapeutic regimens.
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Benzoquinones / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Imidazoles / pharmacology. Lactams, Macrocyclic / pharmacology. Mice. Piperazines / pharmacology. RNA, Small Interfering / genetics. Transcription, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268519.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Benzoquinones; 0 / Imidazoles; 0 / Lactams, Macrocyclic; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


11. Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C: Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion; 2009 Sep;49(9):1890-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
  • BACKGROUND: Lymphocyte recovery after autologous stem cell transplantation (ASCT) has been shown to be associated with positive clinical outcome in non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Hematopoietic Stem Cells / metabolism. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453991.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


12. Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B, French GOELAMS Group: Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study. Haematologica; 2005 Jun;90(6):802-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
  • BACKGROUND AND OBJECTIVES: Most patients with localized high-grade non-Hodgkin's lymphoma (NHL) can be cured with or without adjuvant radiotherapy.
  • Here we report the results of a prospective study, started in 1984, which was conducted to evaluate the long-term outcome of patients with localized high-grade NHL.
  • DESIGN AND METHODS: In this multicenter, prospective study by the GOELAMS group, 253 patients with localized high-grade NHL were treated with 3 cycles of vindesine, cyclophosphamide, adriamycin and prednisone (VCAP, a high-dose CHOP regimen) followed by involved field radiotherapy (40 Gy).
  • With a median follow-up of 88 months, overall survival and disease-free survival rates were 84% and 85% respectively at five years, and 78% and 82% respectively at ten years.
  • INTERPRETATION AND CONCLUSIONS: High-dose CHOP followed by locoregional radiotherapy is a feasible treatment for localized high-grade NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multicenter Studies as Topic. Prednisolone / therapeutic use. Prednisone / therapeutic use. Prospective Studies. Recurrence. Remission Induction. Time Factors. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951293.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CHOP protocol; VAP-cyclo protocol
  •  go-up   go-down


13. Wan SG, Sun XJ, Hui WH, He JJ, Liu CY, Zhao H, Sun WL, Su L, Xu J: [Multiparameter flow cytometric evaluation of bone marrow involvement in B cell non-Hodgkin's lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiparameter flow cytometric evaluation of bone marrow involvement in B cell non-Hodgkin's lymphoma].
  • The objective of study was to evaluate the clinical values of multiparameter flow cytometry (MPFC) and cytomorphology of bone marrow aspiration(BMA) in detecting bone marrow involvement in patients with B cell Non-Hodgkin's lymphoma (B-NHL).
  • Bone marrow involvement in B-NHL detected by MPFC can be useful for clinical evaluation and prognosis prediction.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416192.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).
  • 1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.
  • The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.
  • Moreover, the study indicates that HIV could be used as an effective marker to study the origin and dissemination of lymphomas in vivo.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


15. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L: Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol; 2007 Mar;78(3):206-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
  • BACKGROUND: Early-stage Hodgkin lymphoma (HL) has excellent survival rates but carries a high risk of late treatment-related adverse effects.
  • Modern, individualised therapeutic strategies require an accurate determination of the extent of the disease.
  • FDG-PET/CT would have increased the irradiated volume in seven patients where the volume receiving a minimum of 90% of the target dose was increased by 8-87%.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Hodgkin Disease / radiotherapy. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253974.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • METHODS: We conducted a study using a sequential combination chemotherapy with a reduced cumulative dose of anthracyclines in younger patients with good-prognosis aggressive NHL.
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • The hematological toxicities, particularly after the first and fifth cycle, require the use of G-CSF and/or a dose reduction in selected patients.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1067-73 [11583187.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):536-41 [16098067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1864-71 [15143078.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):277-81 [12562656.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):93-101 [17313557.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):409-16 [18038870.001]
  • [Cites] Ann Oncol. 1993 May;4(5):359-69 [8353070.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D: Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood; 2005 Nov 1;106(9):3166-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
  • We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells.
  • To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS.
  • However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / immunology. Acquired Immunodeficiency Syndrome / virology. Adult. Cell Proliferation. Disease Progression. HIV-1 / immunology. HIV-1 / physiology. Humans. Kinetics. Middle Aged


18. Hubareva HO, Kriachok IA, Tytorenko IB, Aleksyk OM, Novosad OI, Kadnikova TV, Martynchyk AV, Pastushenko IaV, Filonenko KS, Kushchevyĭ IeV: [The treatment of patients with refractory forms of Hodgkin's lymphomas]. Lik Sprava; 2010 Jan-Mar;(1-2):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of patients with refractory forms of Hodgkin's lymphomas].
  • The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20608037.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


19. Bravo LA, Saavedra-Mella FA, Vera F, Guerra A, Cavieres LA, Ivanov AG, Huner NP, Corcuera LJ: Effect of cold acclimation on the photosynthetic performance of two ecotypes of Colobanthus quitensis (Kunth) Bartl. J Exp Bot; 2007;58(13):3581-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caryophyllaceae on their photosynthetic characteristics and performance under high light (HL) were compared.
  • Non-acclimated plants of the Antarctic ecotype exhibited a higher (34%) maximal rate of photosynthesis than the Andes ecotype.
  • In addition, the Antarctic ecotype exhibited higher heat dissipation (NPQ), especially in the cold-acclimated state, which was mainly associated with the fast relaxing component of non-photochemical quenching (NPQ(F)).
  • By contrast, the Andes ecotype exhibited a lower NPQ(F) and a significant increase in the slowly relaxing component (NPQ(s)) at low temperature and HL, indicating higher sensitivity to low temperature-induced photoinhibition.
  • Although the xanthophyll cycle was fully operational in both ecotypes, cold-acclimated Antarctic plants exposed to HL exhibited higher epoxidation state of the xanthophyll cycle pigments (EPS) compared with the cold-acclimated Andes ecotype.
  • Thus, the photosynthetic apparatus of the Antarctic ecotype operates more efficiently than that of the Andes one, under a combination of low temperature and HL.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057038.001).
  • [ISSN] 1460-2431
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Pawlak K, Mysliwiec M, Pawlak D: Chronic viral hepatitis and iron affect the plasma levels of LIGHT--a new member of the TNF superfamily in uraemic haemodialyzed patients. Cytokine; 2007 Sep;39(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We wanted to establish whether the presence of chronic viral hepatitis could be implicated in enhanced inflammation as well as the elevation of plasma LIGHT levels in haemodialyzed (HD) patients.
  • The plasma levels of LIGHT, high sensitivity C-reactive protein (hs CRP) and TNF-alpha were measured in HD patients with hepatitis in comparison to subjects without hepatitis and to healthy volunteers.
  • The values of hs CRP and TNF-alpha were significantly elevated in HD patients when compared to the controls.
  • These results suggest the presence of chronic viral hepatitis and iron levels are novel determinants of the increased LIGHT in the plasma of HD patients.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827030.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / TNFSF14 protein, human; 0 / Tumor Necrosis Factor Ligand Superfamily Member 14; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; E1UOL152H7 / Iron
  •  go-up   go-down


21. Kis LL, Nishikawa J, Takahara M, Nagy N, Matskova L, Takada K, Elmberger PG, Ohlsson A, Klein G, Klein E: In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer; 2005 Mar 1;113(6):937-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.
  • In about 50% of classical Hodgkin lymphomas, the Hodgkin/Reed Sternberg (H/RS) cells carry Epstein-Barr virus (EBV).
  • The viral gene expression in these cells is restricted to EBNA-1, EBERs, LMP-1 and LMP-2 (type II latency).
  • In spite of numerous attempts, only few typical Hodgkin lymphoma (HL) lines have been established.
  • If EBV is expected to drive the cells for growth in culture, the absence of EBNA-2 may explain the incapacity of H/RS cells for in vitro proliferation.
  • For analysis of the interaction between EBV and the H/RS cells, we infected the CD21-positive HL line KMH2 with the B958 and Akata viral strains.
  • In contrast to the type II EBV expression pattern of H/RS cells in vivo, the KMH2 EBV cells did not express LMP-1.
  • The EBV expression pattern could be modified in this type I subline.
  • This result is highly relevant for the type II expression pattern of H/RS cells in vivo, since these stimuli can be provided by the surrounding activated T lymphocytes.
  • [MeSH-major] Bacterial Outer Membrane Proteins / genetics. CD40 Ligand / pharmacology. Epstein-Barr Virus Nuclear Antigens / genetics. Epstein-Barr Virus Nuclear Antigens / pharmacology. Herpesvirus 4, Human / immunology. Hodgkin Disease / immunology. Interleukin-4 / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Humans. Viral Proteins

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15514968.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Lmp1 antigen, Mycoplasma; 0 / Viral Proteins; 147205-72-9 / CD40 Ligand; 207137-56-2 / Interleukin-4
  •  go-up   go-down


22. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger SM, Porter DL, Nasta S, Tsai D, Loren AW, Siegel DL, Glatstein E, Alavi A, Stadtmauer EA, Schuster SJ: Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant; 2006 Aug;38(3):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
  • We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) at our institution.
  • In the FDG-PET-negative group, chemotherapy-resistant patients by CT-based criteria had a comparable outcome to those with chemotherapy-sensitive disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770314.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Valva P, Becker P, Streitemberger P, Lombardi GM, Rey G, Guzman CA, Preciado MV: Germline TP53 mutations and single nucleotide polymorphisms in children. Medicina (B Aires); 2009;69(1 Pt 2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peripheral blood mononuclear cell samples from 26 children with solid tumors [PST] and 21 pediatric healthy donors [HD] were analyzed for germline mutations and polymorphisms in TP53 gene spanning from exon 5 to 8 including introns 5 and 7.
  • A heterozygous mutation at codon 245 was found in 1/26 PST and 0/21 HD.
  • Comparative polymorphisms distribution, at position 14181 and 14201(intron 7), between HD and PST revealed a trend of association (p= 0.07) with cancer risk.
  • HD group disclosed a similar polymorphism distribution as published data for Caucasian and Central/South American populations.
  • [MeSH-major] Genes, p53 / genetics. Germ-Line Mutation. Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adolescent. Argentina. Child. Child, Preschool. Codon. Female. Gene Frequency / genetics. Genetic Predisposition to Disease. Genotype. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414295.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Codon
  •  go-up   go-down


24. Yamada S, Fukuoka K, Miyake M, Miyata S, Nakajima T, Tamura K, Tabata C, Iida S, Kuribayashi K, Uesaka A, Murakami A, Yasumitsu A, Nakano T: [A case of primary lung cancer with cervical tuberculous lymphadenitis]. Nihon Kokyuki Gakkai Zasshi; 2007 Sep;45(9):720-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological examination of the specimen obtained by percutaneous right cervical lymph node biopsy showed necrotizing epithelioid granulomas and no malignant cells.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929476.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Halbsguth TV, Nogová L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood; 2010 Sep 23;116(12):2026-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
  • For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is much worse than for younger HL patients.
  • We thus developed a new regimen, BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone), to improve both tolerability and efficacy of treatment for older HL patients.
  • Between 2004 and 2005, 65 patients with early unfavorable or advanced stage HL aged between 60 and 75 years were enrolled in this phase 2 trial.
  • Fifty-one patients (85%) achieved complete remission, 2 (3%) partial remission, and 4 (7%) developed progressive disease.
  • Thus, the BACOPP regimen is active in older HL patients but is compromised by a high rate of toxic deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Aged. Bleomycin / administration & dosage. Cyclophosphamide. Disease Progression. Doxorubicin / administration & dosage. Drug-Related Side Effects and Adverse Reactions. Female. Germany. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551376.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00284271
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


26. Meacham LR, Gurney JG, Mertens AC, Ness KK, Sklar CA, Robison LL, Oeffinger KC: Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. Cancer; 2005 Apr 15;103(8):1730-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survivors more likely to be underweight included female and male survivors of Hodgkin disease (OR = 1.7; 95% CI, 1.3-2.3 and OR = 3.5; 95% CI, 2.3-5.3) and Wilms tumor (OR = 1.8; 95% CI, 1.2-2.8 and OR = 5.5; 95% CI, 3.1-9.7), female survivors of bone carcinoma without amputation (OR = 1.9; 95% CI, 1.2-2.9), and male survivors of leukemia (OR = 2.4; 95% CI, 1.6-3.6), brain tumors (OR = 2.7; 95% CI, 1.6-4.4), non-Hodgkin lymphoma (OR = 3.1; 95% CI, 1.9-5.2), neuroblastoma (OR = 4.9; 95% CI, 2.48-10.0), and soft tissue sarcoma (OR = 3.5; 95% CI, 2.0-6.0).

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15761876.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Vantová Z, Paulíková H, Sabolová D, Kozurková M, Suchánová M, Janovec L, Kristian P, Imrich J: Cytotoxic activity of acridin-3,6-diyl dithiourea hydrochlorides in human leukemia line HL-60 and resistant subline HL-60/ADR. Int J Biol Macromol; 2009 Aug 1;45(2):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of acridin-3,6-diyl dithiourea hydrochlorides in human leukemia line HL-60 and resistant subline HL-60/ADR.
  • A series of acridin-3,6-diyl-dithiourea hydrochloride derivatives (alkyl-AcrDTU) was prepared and tested against sensitive and drug resistant leukemia cell lines for their cytotoxic/cytostatic activity.
  • All derivatives inhibited proliferation of HL-60 cells and its resistant subline HL-60/ADR, unexpectedly the resistant subline was more sensitive than the parental one (IC(50)=3.5 microM, 48-treatment of HL-60/ADR with pentyl-AcrDTU).
  • [MeSH-minor] Cell Death / drug effects. Cell Proliferation / drug effects. DNA / metabolism. HL-60 Cells. Humans. Spectrometry, Fluorescence. Spectrophotometry, Ultraviolet. Titrimetry. Transition Temperature

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. THIOUREA .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414028.001).
  • [ISSN] 1879-0003
  • [Journal-full-title] International journal of biological macromolecules
  • [ISO-abbreviation] Int. J. Biol. Macromol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acridines; 0 / Antineoplastic Agents; 9007-49-2 / DNA; GYV9AM2QAG / Thiourea
  •  go-up   go-down


28. Uchiyama M, Ikeda T: Pulmonary involvement in systemic Hodgkin's disease. Intern Med; 2009;48(17):1563-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary involvement in systemic Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / radiography. Lung Neoplasms / complications. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721306.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Bogunia-Kubik K, Mazur G, Wróbel T, Kuliczkowski K, Lange A: Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens; 2008 Feb;71(2):146-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.
  • The pathophysiology of Non-Hodgkin's lymphoma (NHL) is still unknown and clinical course is very unpredictable.
  • Many cytokines, including interleukin-10 (IL-10), play a role in the perpetuation of this disease.
  • The aim of the present study was to assess whether any of IL-10 (-1082 A/G, -819 C/T and -592 A/C) genotypes prevails in Polish patients with NHL and whether IL-10 promoter polymorphisms may be associated with less or more favourable course of the disease.
  • The frequency of the IL-10 low-producing -1082 AA homozygous genotype was significantly higher in patients with aggressive NHL as compared with patients with indolent forms of the disease (0.57 vs 0.28, P < 0.05) and controls [0.57 vs 0.32, odds ratio (OR) = 2.69, P < 0.05].
  • Also, the presence of the ACC genotype was more frequently detected among patients with more aggressive disease than in those with indolent forms (0.74 vs 0.47, P < 0.05) and healthy controls (0.74 vs 0.42, OR = 3.69, P < 0.05).
  • [MeSH-major] Interleukin-10 / genetics. Lymphoma, Non-Hodgkin / diagnosis. Polymorphism, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201362.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Genetic Markers; 130068-27-8 / Interleukin-10
  •  go-up   go-down


30. Biswas P, Galli A, Galli L, Tassan Din C, Vecchi A, Malnati M, Lazzarin A, Tambussi G: Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients? Cytometry B Clin Cytom; 2007 Nov;72(6):433-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At T0 PHI subjects presented a statistically significant higher count and percentage of CD8+CCR5+ lymphocytes compared to healthy donors (HD) (mean +/- SD, 2,240 +/- 1,998 vs 181 +/- 89 cells/microl).
  • Conversely, CD4+CXCR4+ lymphocytes were less abundant in PHI than in HD (443 +/- 337 vs 673 +/- 339 cells/microl), whereas CD4+CCR5+ lymphocytes were substantially comparable (169 +/- 167 vs 126 +/- 60 cells/microl).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474134.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CCL5; 0 / Immunosuppressive Agents; 0 / Receptors, CCR5; 0 / Receptors, CXCR4; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


31. Davis BH, Schwartz M: ZAP-70 expression is low in normal precursor B cells or hematogones. Cytometry B Clin Cytom; 2006 Jul 15;70(4):315-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immature or precursor B lymphocytes (hematogones) often occur in clinical samples and coexpress CD10, CD38, and CD19 lacking surface immunoglobulin expression.
  • The present study was carried out in an attempt to further elucidate the role of ZAP-70 in the spectrum of B-cells seen in clinical specimens.
  • In our sample set, the hematogone expression ranged from 2 to 18% of total leukocytes and occurred in a variety of conditions, including CLL, NHL, AML, MDS, Hodgkins Disease, and Multiple Myeloma.
  • The method of ZAP-70 detection was that routinely applied to our clinical testing of CLL samples supplemented with the determination of ZAP-70 levels in the CD38(bright)/CD19(+) coexpressing cells.
  • CONCLUSION: The presence of hematogones in clinical samples should be recognized so as to not adversely influence prognostic studies of ZAP-70 or CD38 in CLL.
  • [MeSH-major] Hematopoietic Stem Cells / metabolism. Hodgkin Disease / immunology. Leukemia / immunology. Multiple Myeloma / immunology. Myelodysplastic Syndromes / immunology. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / biosynthesis


32. Piras G, Monne M, Uras A, Palmas A, Murineddu M, Arru L, Bianchi A, Calvisi A, Curreli L, Gaviano E, Lai P, Murgia A, Latte GC, Noli A, Gabbas A: Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma. Br J Haematol; 2005 Jun;129(6):784-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma.
  • There is strong evidence that altered immunological function entails an increased risk of lymphoma, although the current knowledge of aetiological factors for lymphomas is limited.
  • We analysed the 2q33 chromosomal region harbouring CD28, CTLA4 and ICOS genes, which are closely linked and have related functions in immune regulation, for association in 100 non-Hodgkin's lymphoma (NHL) patients and in 128 healthy controls; both groups originated from Sardinia.
  • [MeSH-major] Antigens, CD28 / genetics. Antigens, Differentiation / genetics. Antigens, Differentiation, T-Lymphocyte / genetics. Chromosomes, Human, Pair 2 / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD. CTLA-4 Antigen. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Inducible T-Cell Co-Stimulator Protein. Linkage Disequilibrium. Male. Microsatellite Repeats. Middle Aged. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953005.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, Differentiation; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein
  •  go-up   go-down


33. Nowakowski GS, Witzig TE: Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol; 2006 Mar;4(3):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
  • Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL).
  • Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab.
  • Both agents target the CD20 antigen on B-cell lymphoma cells.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728934.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Number-of-references] 33
  •  go-up   go-down


34. Durant C, Hervier B, Ansquer C, Masseau A, Hamidou M: Occult Hodgkin lymphoma presenting as polymyalgia rheumatica: value of [18F]-FDG positron emission tomography. Ann Hematol; 2010 Jan;89(1):111-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult Hodgkin lymphoma presenting as polymyalgia rheumatica: value of [18F]-FDG positron emission tomography.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Polymyalgia Rheumatica / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Polymyalgia Rheumatica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633848.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Abdel-Fattah MM, Yassine OG: Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004). Eur J Cancer Prev; 2007 Oct;16(5):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004).
  • During the past decades, the incidence of the most common non-Hodgkin's lymphomas has increased dramatically worldwide.
  • The purpose of this study is to study the problem of non-Hodgkin's lymphomas in Alexandria, Egypt: incidence rates and trend.
  • The method employed was record reviewing for estimation of the annual incidence rates of non-Hodgkin's lymphoma and their trends.
  • The general incidence rate of non-Hodgkin's lymphoma was 5.90 in 1995 and reached 8.99 in 2004, with a peak (9.40) in the year 2002.
  • The male incidence of non-Hodgkin's lymphoma demonstrated an obvious rise from 1995 to 1998, with a slowing from 1999 to 2002, followed by another evident rise from 2003.
  • Women showed an increase in non-Hodgkin's lymphoma incidence rates from 1995 to 2000, then a decline afterwards, till 2004.
  • The incidence of non-Hodgkin's lymphoma increased steadily from 1995 to 2004 in Alexandria, particularly in the elderly population.
  • The importance of developing additional strategies for screening and prevention of non-Hodgkin's lymphoma, in this group, on the basis of epidemiological evidences is warranted.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923821.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Gibbs IC, Tuamokumo N, Yock TI: Role of radiation therapy in pediatric cancer. Hematol Oncol Clin North Am; 2006 Apr;20(2):455-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether in its preventive role of CNS prophylaxis for high-risk ALL, its central role in brain tumors, its adjunct role combined with chemotherapy for disease such as Hodgkin's lymphoma, Ewing's sarcoma, and rhabdomyosarcoma, or its palliative role for metastatic disease, radiation remains an important therapy for pediatric cancers.
  • [MeSH-minor] Adolescent. Brain Neoplasms / radiotherapy. Child. Hodgkin Disease / radiotherapy. Humans. Incidence. Lymphoma, Non-Hodgkin / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Sarcoma / radiotherapy. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730302.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


37. Kasamatsu T, Ogura R, Ikeda N, Morita O, Saigo K, Watabe H, Saito Y, Suzuki H: Genotoxicity studies on dietary diacylglycerol (DAG) oil. Food Chem Toxicol; 2005 Feb;43(2):253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacterial reverse mutation assay (Ames test), the chromosomal aberration assay in cultured Chinese hamster lung cells (CHL/IU), and a bone marrow micronucleus assay in ICR CD mice were employed in the present study.
  • [MeSH-minor] Animals. Bone Marrow / drug effects. Cricetinae. Cricetulus. Dose-Response Relationship, Drug. Hot Temperature. Lung / cytology. Lung / drug effects. Mice. Mice, Inbred ICR. Micronucleus Tests. Microsomes, Liver / drug effects. Obesity / diet therapy. Safety. Salmonella typhimurium / drug effects. Salmonella typhimurium / genetics

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621338.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Diglycerides
  •  go-up   go-down


38. De Giacomo T, Martelli M, Venuta F, Anile M, Diso D, Di Stasio M, Rendina EA, Coloni GF: Lung cancer after treatment for non-Hodgkin lymphoma. Minerva Chir; 2006 Dec;61(6):467-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer after treatment for non-Hodgkin lymphoma.
  • AIM: Because of the improvement in treatment and survival of patients with lymphoma, late sequelae, including secondary cancers have been extensively studied.
  • Lung cancer is one of the two most common solid tumors after Hodgkin's disease but fewer studies have been published about lung cancer after non-Hodgkin lymphoma (NHL).
  • In contrast, the median survival of non surgical patients was 9 months.
  • Comparison of survival between surgical and non-surgical group demonstrated a statistically significant better survival for surgically treated patients (P<0.04).
  • Early diagnosis and treatment is crucial.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Lung Neoplasms. Lymphoma, Non-Hodgkin. Neoplasms, Second Primary. Neuroendocrine Tumors


39. Pulte D, Gondos A, Brenner H: Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma; 2009 Feb;50(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy.
  • An increased risk of non-Hodgkin lymphoma (NHL) has been observed in the survivors of several malignancies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Feb;50(2):145-7 [19235008.001]
  • (PMID = 19197735.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Forero-Torres A, Saleh MN: Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Clin Lymphoma Myeloma; 2007 Dec;8 Suppl 1:S13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.
  • This article provides a review of studies using bendamustine in the treatment of non-Hodgkin lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Nitrogen Mustard Compounds / therapeutic use
  • [MeSH-minor] Alkylating Agents / therapeutic use. Antimetabolites / therapeutic use. Bendamustine Hydrochloride. Clinical Trials as Topic. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Bendamustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282361.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 36
  •  go-up   go-down


41. Ma Y, Visser L, Blokzijl T, Harms G, Atayar C, Poppema S, van den Berg A: The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest; 2008 May;88(5):482-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile.
  • Little is known about the gene expression profile and significance of the rosetting CD4+CD26- T cells in classical Hodgkin's lymphoma (cHL).
  • To characterize these T cells, CD4+CD26- and CD4+CD26+ T-cell populations were sorted from lymph node (LN) cell suspensions from nodular sclerosis HL (NSHL) and reactive LNs. mRNA profiles of stimulated and resting cell subsets were evaluated with quantitative RT-PCR for 46 genes.
  • The resting CD4+CD26- T cells in NSHL showed higher mRNA levels of CD25, CTLA4, OX40 and CCR4 compared with in LNs, supporting a regulatory T-cell (Treg) type, and this was validated by immunohistochemistry.
  • [MeSH-major] CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Dipeptidyl Peptidase 4 / metabolism. Hodgkin Disease / pathology. T-Lymphocytes, Regulatory / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362907.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 56092-81-0 / Ionomycin; EC 3.4.14.5 / Dipeptidyl Peptidase 4; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


42. Snellen IA, de Kok RJ, de Mooij EJ, Albrecht S: The orbital motion, absolute mass and high-altitude winds of exoplanet HD 209458b. Nature; 2010 Jun 24;465(7301):1049-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The orbital motion, absolute mass and high-altitude winds of exoplanet HD 209458b.
  • If the orbital velocity of the planet could be determined, the masses of both star and planet could be calculated using Newton's law of gravity, just as in the case of stellar double-line eclipsing binaries.
  • Here we report high-dispersion ground-based spectroscopy of a transit of the extrasolar planet HD 209458b.
  • We see a significant wavelength shift in absorption lines from carbon monoxide in the planet's atmosphere, which we conclude arises from a change in the radial component of the planet's orbital velocity.
  • A blueshift of the carbon monoxide signal of approximately 2 km s(-1) with respect to the systemic velocity of the host star suggests the presence of a strong wind flowing from the irradiated dayside to the non-irradiated nightside of the planet within the 0.01-0.1 mbar atmospheric pressure range probed by these observations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nature. 2010 Jun 24;465(7301):1017-8 [20577198.001]
  • (PMID = 20577209.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Behler CM, Kaplan LD: Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol; 2006 Sep;18(5):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of HIV-related non-Hodgkin lymphoma.
  • PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of non-Hodgkin lymphoma.
  • Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated non-Hodgkin lymphoma remains an important problem.
  • RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-non-Hodgkin lymphoma.
  • Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or refractory HIV-non-Hodgkin lymphoma.
  • New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-non-Hodgkin lymphoma have also recently been reported.
  • SUMMARY: Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.
  • For aggressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.
  • HIV-associated Burkitt lymphoma should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.
  • Autologous stem cell transplantation should be considered for selected patients with relapsed or refractory HIV-non-Hodgkin lymphoma.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894290.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 65
  •  go-up   go-down


44. Boffetta P, de Vocht F: Occupation and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):369-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupation and the risk of non-Hodgkin lymphoma.
  • Although thus far no occupational agents have been classified as established causes of non-Hodgkin lymphoma (NHL), employment as a farmer, teacher, dry cleaner, meat worker, printer, or wood worker has been associated with elevated risk in the peer-reviewed literature.
  • At present, no conclusive evidence of causal relations between occupations and increased NHL risk exists; this can be ascribed to methodologic problems in studying the link between NHL risk and occupation, including heterogeneity of disease and exposure circumstances and low statistical power.
  • These goals can be best attained within the framework of large-scale, international collaborative projects.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects. Occupations

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372232.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


45. Hermann S, Rohrmann S, Linseisen J, Nieters A, Khan A, Gallo V, Overvad K, Tjønneland A, Raaschou-Nielsen O, Bergmann MM, Boeing H, Becker N, Kaaks R, Bueno-de-Mesquita HB, May AM, Vermeulen RC, Bingham S, Khaw KT, Key TJ, Travis RC, Trichopoulou A, Georgila C, Triantafylou D, Celentano E, Krogh V, Masala G, Tumino R, Agudo A, Altzibar JM, Ardanaz E, Martínez-García C, Suárez MV, Tormo MJ, Braaten T, Lund E, Manjer J, Zackrisson S, Hallmans G, Malmer B, Boffetta P, Brennan P, Slimani N, Vineis P, Riboli E: Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. J Cancer Res Clin Oncol; 2010 Jan;136(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition.
  • INTRODUCTION: Lymphomas belong to the few cancer sites with increasing incidence over past decades, and only a few risk factors have been established.
  • We explored the association between education and the incidence of lymphoma in the prospective EPIC study.
  • MATERIALS AND METHODS: Within 3,567,410 person-years of follow-up, 1,319 lymphoma cases [1,253 non-Hodgkin lymphomas (NHL) and 66 Hodgkin lymphomas (HL)] were identified.
  • Cox proportional hazard regression was used to examine the association between highest educational level (primary school or less, technical/professional school, secondary school, university) and lymphoma risk.
  • RESULTS: Overall, no consistent associations between educational level and lymphoma risk were observed; however, associations were found for sub-groups of the cohort.
  • In both genders, the risk of diffuse large B cell lymphoma (DLBCL) was significantly lower for subjects with university degree (HR = 0.46, 95% CI = 0.27–0.79) versus lowest educational level.
  • No association was found for HL.
  • CONCLUSION: We could not confirm an overall consistent association of education and risk of HL or NHL in this large prospective study; although, education was positively related to the incidence of BCLL and B-NHL (in women) but inversely to incidence of DLBCL.
  • [MeSH-major] Educational Status. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Diet. Europe / epidemiology. Female. Humans. Incidence. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Prevalence. Proportional Hazards Models. Prospective Studies. Risk Assessment / statistics & numerical data. Risk Factors. Sex Factors. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2547-54 [7296505.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:40-61 [17405120.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):813-20 [11714109.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] J Epidemiol Community Health. 2004 Oct;58(10):858-61 [15365113.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Am J Public Health. 2000 Aug;90(8):1277-81 [10937009.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):387-92 [6955544.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):391-401 [17134891.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Int J Epidemiol. 1991 Jun;20(2):354-61 [1917234.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):352-7 [1993542.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):423-7 [2307531.001]
  • (PMID = 19582474.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0401527
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Williamson PJ, de Berker D: Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease. Br J Haematol; 2005 Mar;128(5):582
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bleomycin / adverse effects. Dacarbazine / adverse effects. Doxorubicin / adverse effects. Hair. Hair Diseases / chemically induced. Hodgkin Disease / drug therapy. Vinblastine / adverse effects
  • [MeSH-minor] Adult. Humans. Male. Nail Diseases / chemically induced. Nail Diseases / pathology. Nails. Photography

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725077.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


47. Knutson HA, Charbonneau D, Allen LE, Fortney JJ, Agol E, Cowan NB, Showman AP, Cooper CS, Megeath ST: A map of the day-night contrast of the extrasolar planet HD 189733b. Nature; 2007 May 10;447(7141):183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A map of the day-night contrast of the extrasolar planet HD 189733b.
  • 'Hot Jupiter' extrasolar planets are expected to be tidally locked because they are close (<0.05 astronomical units, where 1 au is the average Sun-Earth distance) to their parent stars, resulting in permanent daysides and nightsides.
  • Here we report observations of HD 189733, the closest of these eclipsing planetary systems, over half an orbital period, from which we can construct a 'map' of the distribution of temperatures.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nature. 2007 May 10;447(7141):155-6 [17495914.001]
  • (PMID = 17495920.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


48. Verberk WJ, Thien T, Kroon AA, Lenders JW, van Montfrans GA, Smit AJ, de Leeuw PW: Prevalence and persistence of masked hypertension in treated hypertensive patients. Am J Hypertens; 2007 Dec;20(12):1258-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Masked hypertension (MH) is defined as a normal blood pressure in the physician's office and an elevated blood pressure when measured out-of-office.
  • The cause of MH may be termed the masked hypertension effect (MHE), and is not restricted to blood-pressure (BP) values around the thresholds for normal BP.
  • We investigated the prevalence and persistence of MH and MHE in patients who were being treated for high BP and who had been followed for a period of 1 year.
  • All measurements were performed with the same type of automatic device.
  • At each visit, MH was determined according to the European Society of Hypertension definition (OBPM, <140/90 mm Hg; SBPM, >/=135 mm Hg or 85 mm Hg).
  • RESULTS: During the entire study, 50% of the patients had MH, and 40% had MHE at 5/3 mm Hg at least once.
  • At four sequential OBPM visits, 2% consistently had MH, and 3% had MHE at 5/3 mm Hg or MHE at 10/6 mm Hg.
  • The prevalence of MH increased with lower OBPM levels but remained rather constant for MHE at 5/3 mm Hg and MHE at 10/6 mm Hg.
  • The persistence of MH and the MHE over time in individual patients was low.
  • CONCLUSIONS: We conclude that MH and MHE at 5/3 mm Hg and MHE at 10/6 mm Hg commonly occur in treated patients, but are not persistent phenomena and probably result from an accidentally low OBPM value on one particular occasion.
  • [MeSH-major] Hypertension / diagnosis. Hypertension / epidemiology

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Hypertens. 2007 Dec;20(12):1266-7 [18047915.001]
  • (PMID = 18047914.001).
  • [ISSN] 0895-7061
  • [Journal-full-title] American journal of hypertension
  • [ISO-abbreviation] Am. J. Hypertens.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN56551999
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM: Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol; 2008 Nov 10;26(32):5170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
  • PURPOSE: Combined-modality therapy is the standard of care for limited-stage Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: We identified 325 patients with limited-stage HL, diagnosed between May 1, 1989 and April 1, 2005, and treated with chemotherapy and radiation therapy following era-specific guidelines: EFRT until 1996; IFRT from 1996 to 2001; INRT < or = 5 cm from 2001 to the present.
  • Exclusion criteria were age younger than 16, fluorine-18 fluorodeoxyglucose positron emission tomography, non-doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy, and/or more than four chemotherapy cycles.
  • RESULTS: At diagnosis, median age was 35 years; 52% male; stage IA 29%; stage IIA 71%.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Lymph Nodes / radiation effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Registries. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838714.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Zinzani PL, Tani M, Alinari L, Molinari AL, Stefoni V, Visani G, Gentilini P, Guardigni L, Fina M, Baccarani M: Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. Leuk Lymphoma; 2005 Oct;46(10):1449-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.
  • Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited.
  • We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like regimen (VNCOP-B) for front-line treatment of elderly aggressive NHL.
  • [MeSH-major] Anemia / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194890.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Alioglu B, Ustun H, Sonmez A, Kaplan H, Arikan FI, Dallar Y: A rare presentation of central nervous system in a pediatric patient with Hodgkin disease: cavernous sinus syndrome. J Pediatr Hematol Oncol; 2009 Oct;31(10):774-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare presentation of central nervous system in a pediatric patient with Hodgkin disease: cavernous sinus syndrome.
  • Intracranial involvement by Hodgkin disease is rare.
  • We report a pediatric patient with Hodgkin disease who had intracranial disease at presentation.
  • Although the most common presenting feature of intracranial Hodgkin disease is cranial nerve palsy with brain parenchyma being the most common intracranial site of involvement, to our best knowledge no pediatric case of Hodgkin disease presented with isolated cavernous sinus syndrome reported.
  • We report this rare case because of its unusual presentation, in which Hodgkin disease presented with cavernous sinus syndrome.
  • Physicians should consider the probability of Hodgkin disease in children of all ages who present with cavernous sinus syndrome.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cavernous Sinus / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Diagnostic Imaging. Humans. Male. Nervous System Diseases / etiology. Ophthalmoplegia. Remission Induction. Syndrome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641468.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Jetsrisuparb A, Wiangnon S, Komvilaisak P, Kularbkaew C, Yutanawiboonchai W, Mairieng E: Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma. J Pediatr Hematol Oncol; 2005 Apr;27(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
  • This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma.
  • Transient neutropenia and lymphopenia occurred but with no clinical significance.
  • The boy has been disease-free for the last 48 months (after 64 months of follow-up); his organ functions are normal.
  • Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838396.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


53. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • Status at transplantation was the most predictive factor for the survival after HDC/PBSCT (EFS for CR 70.8+/-9.5% vs non-CR 20.0+/-17.9%, P = 0.008).
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Schwaller J, Went P, Matthes T, Dirnhofer S, Donze O, Mhawech-Fauceglia P, Myit S, Huard B: Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's Disease. Leukemia; 2007 Jun;21(6):1324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's Disease.
  • [MeSH-major] Hodgkin Disease / pathology. Tumor Necrosis Factor Ligand Superfamily Member 13 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315017.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TNFSF13 protein, human; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


55. Falcão S, Mourão AF, Ribeiro C, Pinto TL, Mateus M, Araújo P, Nero P, Pimentão JB, Branco JC: [Eosinophilic fasciitis and aplastic anemia]. Acta Reumatol Port; 2009 Jan-Mar;34(1):120-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several cases of eosinophilic fasciitis and serious haematological disorders such as immune thrombocytopenia, Hodgkin's disease and aplastic anaemia have been described.
  • The authors report an atypical severe case of eosinophilic fasciitis complicated by aplastic anaemia non responsive to treatment.


56. de Bot ST, Dorresteijn LD, Haaxma CA, Kappelle AC, van de Warrenburg BP: [From psychiatric symptoms to paraneoplastic syndrome]. Tijdschr Psychiatr; 2008;50(9):603-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Van psychiatrisch symptoom tot paraneoplastisch syndroom.
  • The first patient suffered from a mood disorder, personality changes and complained of several, hitherto unexplained physical symptoms.
  • Finally the patient was diagnosed with paraneoplastic cerebellar degeneration associated with Hodgkin's disease.
  • These cases illustrate that patients with paraneoplastic neurological syndromes may present with psychiatric symptoms which can hamper an early diagnosis.
  • [MeSH-major] Hodgkin Disease / psychology. Ovarian Neoplasms / psychology. Paraneoplastic Syndromes, Nervous System / psychology. Teratoma / psychology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tijdschr Psychiatr. 2008;50(11):755-6 [18991237.001]
  • (PMID = 18785107.001).
  • [ISSN] 0303-7339
  • [Journal-full-title] Tijdschrift voor psychiatrie
  • [ISO-abbreviation] Tijdschr Psychiatr
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Mohapatra PR, Bhuniya S, Garg S, Dimri K, Janmeja AK: Endobronchial non-Hodgkin's lymphoma presenting as mass lesion. Indian J Chest Dis Allied Sci; 2009 Apr-Jun;51(2):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial non-Hodgkin's lymphoma presenting as mass lesion.
  • A 40-year-old male presented with clinical and radiological manifestations of right lung atelectasis and post-obstructive pneumonia.
  • Endobronchial biopsy from the mass lesion yielded low grade B-cell non-Hodgkin's lymphoma.
  • This is one of the rarest presentation of non-Hodgkin's lymphoma.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445447.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


58. Rudant J, Menegaux F, Leverger G, Baruchel A, Lambilliotte A, Bertrand Y, Patte C, Pacquement H, Vérité C, Robert A, Michel G, Margueritte G, Gandemer V, Hémon D, Clavel J: Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE). Cancer Causes Control; 2008 Dec;19(10):1277-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 765 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 165 of non-Hodgkin's lymphoma (NHL) and 1681 controls were included.
  • For the four diseases, the ORs significantly increased with the number of cigarettes smoked.
  • No association with HL or with other types of NHL was observed.
  • [MeSH-major] Alcohol Drinking / adverse effects. Hematologic Neoplasms / classification. Hematologic Neoplasms / epidemiology. Prenatal Exposure Delayed Effects. Smoking / adverse effects
  • [MeSH-minor] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Case-Control Studies. Child. Child, Preschool. Female. France / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Incidence. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / pathology. Logistic Models. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Maternal Exposure / adverse effects. Odds Ratio. Paternal Exposure / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pregnancy. Registries / statistics & numerical data. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618277.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


59. Mondin V, Ferlito A, Devaney KO, Woolgar JA, Rinaldo A: A survey of metastatic central nervous system tumors to cervical lymph nodes. Eur Arch Otorhinolaryngol; 2010 Nov;267(11):1657-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the realm of head and neck diseases, one particularly common clinical presentation is that of the patient with a cervical mass.
  • In children, neck masses often prove to be developmental cysts; in adults, the recent onset of a neck mass can signal a metastasis from a head and neck squamous carcinoma.
  • Less often, both adults and children may present with cervical masses caused by either non-Hodgkin's lymphoma or Hodgkin's disease.
  • Cervical node metastases may arise from glial tumors (including glioblastoma multiforme, in both adult and pediatric patients) and non-glial tumors (such as medulloblastoma in pediatric patients).
  • The history of a previous intracranial lesion is often the key to correct diagnosis, since, without prompting, neither the pathologist nor the radiologist is likely to think of a cervical node metastasis from a brain tumor when assessing a cervical mass of unknown etiology.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1980 Oct;53(4):562-5 [7420182.001]
  • [Cites] Radiology. 1966 Jul;87(1):55-63 [4287332.001]
  • [Cites] Acta Neuropathol. 2003 Apr;105(4):309-27 [12624784.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Jun;47(6):273-7 [17587781.001]
  • [Cites] Neurochirurgie. 1976;22(6):653-69 [193060.001]
  • [Cites] J Korean Med Sci. 2004 Dec;19(6):911-4 [15608410.001]
  • [Cites] Acta Neurochir (Wien). 1981;57(1-2):99-105 [6267905.001]
  • [Cites] Hum Pathol. 1979 Jul;10(4):453-67 [381159.001]
  • [Cites] Neuropathology. 2003 Jun;23 (2):146-9 [12777104.001]
  • [Cites] J Neurooncol. 1988;6(1):53-9 [3294352.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):187-90 [16645723.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(5-6):342-9 [8729851.001]
  • [Cites] W V Med J. 1998 Sep-Oct;94(5):276-8 [9803886.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):180-4 [2162242.001]
  • [Cites] J Neurosurg. 1974 Feb;40(2):206-12 [4809119.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1975 Mar;74(3):220-8 [167101.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Mar;48(3):229-38 [19025795.001]
  • [Cites] J Cancer Res Ther. 2007 Apr-Jun;3(2):102-4 [17998733.001]
  • [Cites] Am J Med Sci. 1989 Aug;298(2):109-18 [2669475.001]
  • [Cites] Cytopathology. 1997 Dec;8(6):421-7 [9439895.001]
  • [Cites] Arch Pathol. 1962 Mar;73:223-9 [14461268.001]
  • [Cites] J Neurol. 1982;227(3):151-5 [6181222.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4111-7 [8508376.001]
  • [Cites] Neuro Oncol. 2003 Jan;5(1):14-8 [12626129.001]
  • [Cites] Tumori. 1984 Aug 31;70(4):389-92 [6474586.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):872-7 [2033446.001]
  • [Cites] Acta Neuropathol. 1981;54(4):269-73 [7270083.001]
  • [Cites] Acta Neurochir (Wien). 2008 Jul;150(7):699-702; discussion 702-3 [18548193.001]
  • [Cites] J Pathol. 1973 Apr;109(4):335-43 [4720914.001]
  • [Cites] Brain. 1961 Jun;84:301-9 [13733291.001]
  • [Cites] Pediatr Neurosurg. 1994;20(4):269-71 [8043466.001]
  • [Cites] Neurology. 1989 Dec;39(12):1593-6 [2685656.001]
  • [Cites] Neoplasma. 1962;9:585-92 [13991553.001]
  • [Cites] Br J Neurosurg. 1994;8(1):87-92 [8011201.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):974-81 [6692295.001]
  • [Cites] Pathology. 1984 Apr;16(2):217-21 [6087260.001]
  • [Cites] J Neurooncol. 2010 May;97(3):451-7 [19898745.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Apr;50(2):422-5 [17883098.001]
  • [Cites] J Neurosurg. 1961 May;18:313-30 [13761772.001]
  • [Cites] Surg Neurol. 1977 Nov;8(5):347-9 [199955.001]
  • [Cites] Neurol Neurochir Pol. 1971 Sep-Oct;5(5):753-7 [5161087.001]
  • [Cites] Cancer. 1976 Mar;37(3):1577-83 [177171.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Pathology. 2009 Feb;41(2):197-9 [19152196.001]
  • [Cites] Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90 [19484696.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):755-6 [1320896.001]
  • [Cites] J Neurosurg. 1974 Nov;41(5):607-9 [4371027.001]
  • [Cites] Duodecim. 1974;90(24):1744-8 [4374348.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Zentralbl Neurochir. 1975;36(1):27-36 [1224866.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):575-86 [11534674.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] No Shinkei Geka. 1979 Oct;7(10 ):1005-10 [522948.001]
  • [Cites] Clin Neuropathol. 2005 Nov-Dec;24(6):247-51 [16320817.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1427-30 [15690330.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1982 Fall;4(3):259-62 [7149167.001]
  • [Cites] Br J Surg. 1951 Jul;39(153):56-65 [14858828.001]
  • [Cites] Arkh Patol. 1960;22(4):78-80 [13804641.001]
  • [Cites] Brain. 1964 Jun;87:379-412 [14188281.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):107-11 [16600659.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1969 Jun;32(3):249-53 [5795118.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):90-2 [3817801.001]
  • [Cites] No Shinkei Geka. 1986 Jan;14(1):59-65 [3951664.001]
  • [Cites] Vopr Onkol. 2009;55(2):230-6 [19514382.001]
  • [Cites] Neurosurgery. 1981 Mar;8(3):391-6 [7242888.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Clin Neurosci. 2009 Nov;16(11):1485-6 [19581092.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):60-5 [8807254.001]
  • [Cites] Arch Neurol. 1968 Jun;18(6):649-53 [5652993.001]
  • [Cites] Am J Otolaryngol. 1983 Sep-Oct;4(5):297-324 [6416092.001]
  • [Cites] Arkh Patol. 1958 Jun;20(6):83-6 [13560319.001]
  • [Cites] J Lancet. 1964 Jul;84:227-9 [14153500.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] Neurol Med Chir (Tokyo). 2010;50(2):161-4 [20185886.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):669-73 [15684601.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] Pathologe. 1993 Dec;14(6):386-90 [8121896.001]
  • [Cites] J Neurosurg. 1967 Dec;27(6):568-73 [6065130.001]
  • [Cites] Arkh Patol. 1979;41(11):68-70 [518368.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(1):25-9 [11345714.001]
  • [Cites] J Pathol Bacteriol. 1959 Jul;78:187-95 [14439916.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):226-31 [4540397.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1992 May;49(5):354-64 [1320996.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1271-86 [17908533.001]
  • [Cites] Ann Saudi Med. 1997 May;17(3):340-3 [17369737.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Jan;54(1):80-6 [2010766.001]
  • [Cites] Diagn Cytopathol. 1994;11(1):68-73 [7956665.001]
  • [Cites] Acta Neurochir (Wien). 1976;35(4):247-59 [998355.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1929-31 [8933881.001]
  • [Cites] Rev Esp Otoneurooftalmol Neurocir. 1951 Sep-Oct;10(57):313-6 [14920995.001]
  • [Cites] J Laryngol Otol. 1991 Mar;105(3):229-31 [2019817.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Nov;38(11):1133-5 [1206423.001]
  • [Cites] Pediatr Dev Pathol. 2009 May-Jun;12(3):244-8 [19086745.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7 [18981882.001]
  • [Cites] Childs Nerv Syst. 1990 May;6(3):179-82 [2162735.001]
  • [Cites] J Neurosurg. 1977 Nov;47(5):766-70 [908941.001]
  • [Cites] Acta Neurochir (Wien). 1959;7:263-73 [13805555.001]
  • [Cites] Can J Neurol Sci. 1981 May;8(2):115-9 [7296419.001]
  • [Cites] Arch Derm Syphilol. 1949 Jun;59(6):626-35 [18151073.001]
  • [Cites] Z Krebsforsch. 1955;60(5):590-6 [13300505.001]
  • [Cites] Am J Otolaryngol. 1983 Jan-Feb;4(1):74-6 [6324605.001]
  • [Cites] No To Shinkei. 1972 Mar;14 (3):339-51 [4335553.001]
  • [Cites] Psychiatr Neurol Med Psychol (Leipz). 1971 Mar;23(3):167-74 [4330749.001]
  • [Cites] Surg Neurol. 1979 Oct;12(4):337-9 [524254.001]
  • [Cites] Zentralbl Neurochir. 1952;12(6):347-56 [13091280.001]
  • [Cites] J Oral Pathol Med. 1997 Sep;26(8):388-92 [9379431.001]
  • [Cites] Cancer. 1958 Sep-Oct;11(5):888-94 [13585341.001]
  • [Cites] J Neurosurg. 1973 May;38(5):631-4 [4351224.001]
  • [Cites] Clin Neuropathol. 1988 May-Jun;7(3):131-3 [3203482.001]
  • [Cites] Klin Padiatr. 1987 Jan-Feb;199(1):19-21 [3560762.001]
  • [Cites] No Shinkei Geka. 1985 Nov;13(11):1245-50 [4088447.001]
  • [Cites] J Neurosurg. 1974 Feb;40(2):255-9 [4809126.001]
  • [Cites] Pathol Res Pract. 2009;205(7):502-7 [19410385.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] Am J Clin Pathol. 1963 Feb;39:148-60 [13939379.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):265-71 [15015656.001]
  • [Cites] Ann Neurol. 1980 Feb;7(2):113-7 [7369716.001]
  • [Cites] J Neurosurg. 1967 May;26(5):542-7 [6025328.001]
  • [Cites] Psychiatr Neurol Neurochir. 1967 Jul-Aug;70(4):245-59 [6052791.001]
  • [Cites] J Comput Assist Tomogr. 1990 Mar-Apr;14(2):294-6 [2312862.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64(3):294-8 [5855579.001]
  • [Cites] Tumori. 2008 Jan-Feb;94(1):40-51 [18468334.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Dec;59(12):1044-50 [11138924.001]
  • (PMID = 20694730.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


60. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI: Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
  • The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m(2) per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy.
  • Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cause of Death. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Rituximab. Survival Analysis. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


61. Dupuis J, Haioun C: [Non-Hodgkin lymphoma in the elderly]. Bull Cancer; 2008 May 28;95 FMC Onco:F79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma in the elderly].
  • [Transliterated title] Lymphomes non hodgkiniens du sujet âgé: lymphome à grandes cellules B et lymphome folliculaire.
  • Non-Hodgkin's lymphomas form a heterogeneous group of tumors whose incidence is rising in elderly subjects.
  • Two approaches can thus be proposed: the first is to give the patient a conventional treatment with a higher risk of toxicity, the second one would be to propose a "lighter", dose-adapted treatment.
  • Two examples are examined more closely: diffuse large B-cell lymphomas and follicular lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Humans. Life Expectancy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511372.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P: Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol; 2005 Aug;75(2):116-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.
  • We studied the impact of CHOP chemotherapy on the quality of life (QoL) of elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
  • At baseline, QoL was significantly better on almost all dimensions in patients with a lower compared to patients with a higher age-adjusted International Prognostic Index (aaPI).
  • During follow-up, the QoL was significantly better for patients in complete response (CR) or partial remission (PR) than for patients with progression/relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Quality of Life

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005.
  • (PMID = 16000127.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


63. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, D'Agostino C, Vullo V, Mastroianni CM: Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS; 2007 Mar 30;21(6):677-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Culture supernatants were collected from PBMC isolated from 46 HIV-infected subjects and 19 healthy donors (HD).
  • RESULTS: MMP-9 was significantly elevated in culture supernatants from PBMC of ART-naive subjects in comparison with HD.
  • Analysis by the reverse transcriptase polymerase chain reaction indicated that MMP-9 expression was increased in ART-naive subjects in comparison with HD but ART induced a decrease of MMP-9 expression to levels comparable with those of HD.
  • By contrast, in both HD and ART-treated subjects, there was no MMP-9 activity, indicating that MMP-9 was completely blocked by binding to its natural tissue inhibitor TIMP-1.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413688.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / HIV Protease Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Reverse Transcriptase Inhibitors; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


64. Büyükpamukçu M, Varan A, Akyüz C, Atahan L, Ozyar E, Kale G, Köksal Y, Kutluk T: The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol; 2009;48(1):44-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of childhood Hodgkin lymphoma: improved survival in a developing country.
  • BACKGROUND: To evaluate the clinical characteristics, treatment regimens, and outcome of children with Hodgkin lymphoma in a developing country over a period of 34 years.
  • METHODS: This paper retrospectively evaluates the treatment and prognosis of 614 children with Hodgkin lymphoma disease between 1971 and 2005.
  • Histopathologic subtypes were mixed cellularity (344 patients), nodular sclerosis (90), lymphocytic predominance (62), lymphocytic depletion (46), unclassified types (69), and nodular lymphocyte predominant Hodgkin lymphoma (3).
  • Overall (OS) and event-free survival (EFS) rates were 83 and 60%, though OS rates varied according to chemotherapy protocol; age; presence of B symptoms, leukocytosis, anemia, and extranodal involvement; and stage at diagnosis.
  • Over the years, the median age of patients increased, as did the frequency of the nodular sclerosing type of disease.
  • The increase in the median age and in the frequency of the nodular-sclerosing type are thought to be related to the development status of Turkey.
  • The ABVD protocol yielded the best survival rates and should be used for treatment of patients with Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / therapy


65. Aleman BM, Girinsky T, van der Maazen RW, Strijk S, Meijnders P, Bortolus R, Olofsen-van Acht MJ, Lybeert ML, Lievens Y, Eghbali H, Noordijk EM, Tomsic R, Meerwaldt JH, Poortmans PM, Smit WG, Pinna A, Henry-Amar M, Raemaekers JM, European Organization for Research, Treatment of Cancer (EORTC) Lymphoma Group: Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1184-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
  • PURPOSE: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin's lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy.
  • METHODS AND MATERIALS: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed.
  • Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose <90% of the prescribed dose.
  • The total dose was correct in 81% of the patients.
  • There was no relationship between incidence or site of relapse and major protocol violations.
  • CONCLUSION: In advanced-stage HL patients in complete remission after six to eight cycles of MOPP-ABV, the outcome was not influenced by violation of the radiotherapy protocol.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Quality Control

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936157.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP protocol; VBA protocol
  •  go-up   go-down


66. Macdonald DA, Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM: Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol; 2007 Oct;18(10):1680-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.
  • BACKGROUND: In the National Cancer Institute of Canada Clinical Trials Group/Eastern Cooperative Oncology Group HD.6 trial, progression-free survival was better in patients randomized to therapy that included radiation, compared to doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) alone.
  • CONCLUSION: Treatment that includes radiation reduces the risk of progressive Hodgkin lymphoma in sites that receive this therapy, but we are unable to detect differences in FF2P or FF2P/D.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846017.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


67. Gao S, Han H, Feng HL, Zhao SJ, Meng QW: Overexpression and suppression of violaxanthin de-epoxidase affects the sensitivity of photosystem II photoinhibition to high light and chilling stress in transgenic tobacco. J Integr Plant Biol; 2010 Mar;52(3):332-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and suppression of violaxanthin de-epoxidase affects the sensitivity of photosystem II photoinhibition to high light and chilling stress in transgenic tobacco.
  • Tobacco (Nicotiana tabacum) transformed with the sense and antisense constructs of tomato (Lycopersicon esculentum) violaxanthin de-epoxidase gene (LeVDE) was obtained under the control of the cauliflower mosaic virus 35S promoter (35S-CaMV).
  • Wild type (WT), the sense-transgenic line T(1)-24(+) and the antisense-transgenic line T(1)-17(-) were used for physiological measurement.
  • The ratio of (A+Z)/(V+A+Z) and non-photochemical quenching in WT were lower than that in sense plants and higher than that in antisense ones under high light and chilling stress with low irradiance.
  • The maximal photochemical efficiency of photosystem II (PSII) (Fv/Fm) and the net photosynthetic rate (Pn) in the sense line decreased less, while Fv/Fm and Pn in the antisense line decreased most obviously among all lines.
  • These results suggest that the expression of the violaxanthin de-epoxidase gene in transgenic plants affects the sensitivity of PSII photoinhibition to high light and chilling stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377694.001).
  • [ISSN] 1744-7909
  • [Journal-full-title] Journal of integrative plant biology
  • [ISO-abbreviation] J Integr Plant Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Photosystem II Protein Complex; 0 / RNA, Antisense; 0 / Xanthophylls; EC 1.- / Oxidoreductases; EC 1.- / violaxanthin de-epoxidase
  •  go-up   go-down


68. van der Meer MA, Knierim JJ, Yoganarasimha D, Wood ER, van Rossum MC: Anticipation in the rodent head direction system can be explained by an interaction of head movements and vestibular firing properties. J Neurophysiol; 2007 Oct;98(4):1883-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rodent head-direction (HD) system, which codes for the animal's head direction in the horizontal plane, is thought to be critically involved in spatial navigation.
  • Electrophysiological recording studies have shown that HD cells can anticipate the animal's HD by up to 75-80 ms.
  • In this modeling study, we provide a novel explanation for HD anticipation that relies on the firing properties of neurons afferent to the HD system.
  • In addition, HD anticipation varies between recording sessions of the same cell, between active and passive movement, and between different studies.
  • We conclude that HD afferent dynamics and the statistics of rat head movements are important in generating HD anticipation.
  • This result contributes to understanding the functional circuitry of the HD system and has methodological implications for studies of HD anticipation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17596421.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS39456
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. You Y, Xia LH, Zhang C, Liu F, Chen ZC, Zou P: [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases]. Zhonghua Yi Xue Za Zhi; 2007 Nov 27;87(44):3127-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases].
  • OBJECTIVE: To investigate the clinical effect of peripheral blood progenitor (PBPC) selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma (NHL) patients.
  • METHODS: Peripheral blood was collected from 5 NHL patients, 3 males and 2 females, aged 29 (14 - 58), t3 with T cell NHL, 1 with diffused large B cell NHL and 1 with genuine histiocytic lymphoma, 2 at the IIA stage and 3 at the IVB stage, and 4 in their first complete remission (CR1) period, and 1 in partial remission (PR2).
  • RESULTS: Magnetic-activated cell sorting resulted in 3.3 log depletion of CD34(-) cells and a median yield of CD34(+) selected cells was reinfused with the dose of 2.0 x 10(6)/kg.
  • CONCLUSION: Brings prompt and stable engraftment, autologous selected PBPC CD34(+) cells transplantation may safely improve the clinical outcome of the patients with NHL.
  • [MeSH-major] Antigens, CD34 / blood. Lymphoma, Non-Hodgkin / surgery. Peripheral Blood Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269872.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


70. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL: A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant; 2005 Mar;35(6):557-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
  • There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT).
  • We developed a prognostic model for event-free survival (EFS) post-BMT based on HD patient characteristics measured at the time of autologous (auto) or allogeneic (allo) BMT.
  • Between 1/1991 and 12/2001, 64 relapsed or refractory HD patients received an auto (n=46) or allo (n=18) BMT.
  • Significant multivariate predictors of shorter EFS were chemotherapy-resistant disease, KPS <90 and > or =3 chemotherapy regimens pre-BMT.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation. Prognosis
  • [MeSH-minor] Adult. Cause of Death. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft Survival. Humans. Male. Middle Aged. Models, Theoretical. Multivariate Analysis. Salvage Therapy. Survival Analysis. Time. Transplantation, Autologous. Transplantation, Homologous


71. Ryerson CJ, Churg A, Wilcox PG: A 48-year-old woman with remote hodgkin disease and bilateral pleural effusions. Chest; 2009 Sep;136(3):934-937
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 48-year-old woman with remote hodgkin disease and bilateral pleural effusions.
  • [MeSH-major] Hodgkin Disease / complications. Mesothelioma / diagnostic imaging. Peritoneal Neoplasms / diagnostic imaging. Pleural Effusion, Malignant / diagnostic imaging. Pleural Effusion, Malignant / etiology. Pleural Neoplasms / diagnostic imaging
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Laparoscopy. Middle Aged. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736198.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Pan ZH, Huang HQ, Lin XB, Xia YF, Xia ZJ, Peng YL, Cai QQ, Lin TY, Jiang WQ, Guan ZZ: [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng; 2005 Dec;24(12):1493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
  • BACKGROUND & OBJECTIVE: Nasal-type NK/T-cell non-Hodgkin's lymphoma (NHL) is a unique subtype with the manifestation of local necrosis, infection and fever.
  • The efficacy of chemotherapy alone is unsatisfactory; while radiochemotherapy plays some roles in the management of NK/T-cell lymphoma (NK/TCL).
  • This study was to summarize the clinical characteristics, treatment outcome and prognosis of NK/TCL patients.
  • All the patients were classified according to WHO classification system.
  • The disease course was 1-24 months with a median of 6.5 months.
  • Of the 93 patients, 15 (16.1%) presented perforation of hard palate and/or nasal septum, 35 (37.6%) presented B symptoms; 35 (37.6%) were treated with chemotherapy alone, 2 (2.2%) were treated with radiotherapy alone, 54 (58.0%) were treated with radiochemotherapy, and 2 (2.2%) received no treatment.
  • The first-line chemotherapy regimens were mainly CHOP and EPOCH.
  • Multivariate analysis showed that perforation of hard palate and/or nasal septum, B symptoms and therapeutic modality were independent prognostic factors of NK/TCL (P=0.035, P<0.001, and P=0.004).
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell. Nose Neoplasms

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351799.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


73. Lehmberg K, Steinhausen B, Janka G: From neonates to adolescents--the diagnostic significance of pitted erythrocytes in hyposplenic and asplenic children. Klin Padiatr; 2007 Nov-Dec;219(6):339-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Splenic function may be reduced or absent in a range of medical conditions in childhood, most prominently in homozygous sickle cell disease, celiac disease, or after total or partial splenectomy.
  • In neonates and patients with malignant disease, transient hyposplenia has been reported as well.
  • A simple method with reliable reference values is required to determine a patient's splenic function and thereby assess the risk of systemic infection.
  • This included splenectomized individuals, patients at risk for hyposplenia (homozygous sickle cell anemia (HbSS), leukemia, nephroblastoma and Hodgkin's disease after irradiation, patients after stem cell transplantation (SCT)), term and preterm neonates, and 90 controls (0-20 years of age, no neonates).
  • For clinical purposes, the degree of hyposplenia can be determined to give an estimation of the risk of severe infection, e.g. in patients with HbSS or after partial splenectomy.
  • [MeSH-major] Anemia, Sickle Cell / diagnosis. Erythrocytes, Abnormal. Spleen / physiology. Splenectomy

  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050044.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Pongpruttipan T, Sitthinamsuwan P, Rungkaew P, Ruangchira-urai R, Vongjirad A, Sukpanichnant S: Pitfalls in classifying lymphomas. J Med Assoc Thai; 2007 Jun;90(6):1129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pitfalls in classifying lymphomas.
  • BACKGROUND: Although the WHO classification (2001) requires a great deal of morphologic, immunophenotypic, genetic, and clinical features for classifying lymphomas, it is still feasible to misdiagnose under limited resources, especially a limited panel of antibodies used for immunophenotyping.
  • To identify pitfalls in classifying lymphomas among hematopathologist, general pathologists, and pathology residents under this situation.
  • MATERIAL AND METHOD: Newly diagnosed lymphoma cases from 1 July 2002 to 30 June 2003 at Siriraj Hospital were included for two rounds of individually blinded review by a hematopathologist, two general pathologists, and three pathology residents.
  • RESULTS: One hundred and four lymphoma cases included 61 diffuse large B-cell lymphoma (DLBCL, 58.6%), 12 MALT lymphoma (11.5%), eight follicular lymphoma (FL, 7.7%), seven classical Hodgkin lymphoma (HL, 6.7%), four unspecified peripheral T-cell lymphoma (PTCL, 3.8%), three Burkitt lymphoma (BL, 2.9%), two subcutaneous panniculitis-like T-cell lymphoma (SPTCL, 1.9%), and seven other uncommon types (1% each).
  • Pitfalls were low infrequency on diagnosis of DLBCL, nodular sclerosis HL, and SPTCL (8% each), but not different among the participants only in DLBCL.
  • Pitfalls in diagnosis of MALT lymphoma, mixed cellularity HL, BL, unspecified PTCL, and FL were 60%, 50%, 33%, 29%, and 24%, respectively.
  • However, considering hematopathologist and non-hematopathologist groups, pitfalls in the former were lower, especially in the uncommon types of lymphoma.
  • CONCLUSION: Pitfalls in classifying lymphomas are common.
  • Interest in hematopathology reduces misdiagnosis in lymphomas other than DLBCL.
  • [MeSH-major] Diagnostic Errors. Immunophenotyping / standards. Lymphoma / classification
  • [MeSH-minor] Humans. Pathology, Clinical / education. Pathology, Clinical / standards. Pilot Projects. Thailand. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624207.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


75. McPhee E, Eskander JP, Eskander MS, Mahan ST, Mortimer E: Imaging in pelvic osteomyelitis: support for early magnetic resonance imaging. J Pediatr Orthop; 2007 Dec;27(8):903-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result, accurate diagnosis is often delayed, and children may undergo surgical diagnostic or therapeutic procedures that may be avoided.
  • We report the radiographic and magnetic resonance imaging (MRI) findings in 23 children admitted with a suspected diagnosis of pelvic osteomyelitis.
  • We are presenting imaging findings in children with suspected pelvic osteomyelitis with emphasis on MRI abnormalities and to propose an anatomical classification based on the patterns of pelvic involvement.
  • Criteria were defined for the diagnosis of pelvic osteomyelitis based on criteria used by Farley et al in 1985.
  • Specific attention was paid to the imaging strategies used and the influence of each radiographic method on the ultimate diagnosis.
  • One patient had a noninfectious cause of presentation with a deep vein thrombosis, whereas another was diagnosed with Hodgkin lymphoma in addition to osteomyelitis of the ischium.
  • In patients presenting with clinical findings and laboratory studies suggesting an infectious process, MRI with gadolinium enhancement should be performed as an early study.
  • [MeSH-minor] Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209613.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Basecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B, Schmitz N, Trumper L, Griesinger F: Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol; 2008 Apr;141(1):52-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.
  • Therapy-associated myelodysplastic syndromes and acute myeloid leukaemia (t-AML/MDS) following high dose chemotherapy are significant problems, with a cumulative incidence of 20% or more in myeloablative treatment regimen.
  • To determine the incidence of post-therapeutic aberrations and their predictive value, we prospectively investigated 316 samples of 95 patients with non-Hodgkin lymphoma (NHL) who were treated with intermediate and high dose chemotherapy (Arm A and B of the megaCHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisolone) trial of the German High Grade NHL study group).
  • Cytogenetic analysis of 53 NHL patients after high dose therapy showed frequent chromosomal breakage.
  • None of these patients developed a t-AML/MDS during a 3-year clinical follow up period.
  • We concluded that the high incidence of genetic aberrations reflected a dose-dependent, transient therapy-induced genetic damage which is not predictive of a t-AML/MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosome Aberrations / drug effects. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Follow-Up Studies. Humans. Leukemia, Myeloid, Acute / chemically induced. Middle Aged. Prednisolone / therapeutic use. Prognosis. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction / methods. Translocation, Genetic. Vincristine / therapeutic use


77. Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, Hanau G, Fossati F, Pillon M, Rondelli R, Sandri A, Silvestri D, Haupt R, Cuttini M: Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer; 2006 Oct 15;47(5):560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the long-term outcome of children treated for a solid tumor who relapsed after the elective end of therapy, and to explore factors associated with survival.
  • METHODS: All patients with the selected diagnoses-Hodgkin disease (HD), neuroblastoma (NB), tumor of the central nervous system (CNS), Wilms tumor (WT), or soft tissue sarcoma (STS)-enrolled in the Italian Pediatric Off-Therapy Registry in the period 1980-1998 were evaluated.
  • There were significant differences according to the original diagnosis, with patients with HD doing better, and those with NB, CNS, and STS worse.
  • [MeSH-major] Hodgkin Disease / diagnosis. Nervous System Neoplasms / diagnosis. Neuroblastoma / diagnosis. Registries. Sarcoma / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Italy. Male. Prognosis. Recurrence. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Homologous. Treatment Outcome


78. Long JM: Treatment approaches and nursing applications for non-Hodgkin lymphoma. Clin J Oncol Nurs; 2007 Feb;11(1 Suppl):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment approaches and nursing applications for non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL), a malignancy that manifests in the lymphatic system, is one of the most commonly occurring hematologic disease types in the United States and other Westernized countries.
  • NHL is divided into a range of subtypes with differing clinical features and outcomes.
  • Depending on the type of NHL and the patient's overall clinical presentation, treatment varies from systemic combined chemotherapy regimens with or without immunotherapy, radioimmunotherapy, and transplants to investigational options.
  • Oncology nurses play a vital role in implementing successful treatment and management of patients with NHL as oncology care moves into an era of novel targeted therapies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / nursing. Lymphoma, Non-Hodgkin / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471823.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors
  •  go-up   go-down


79. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


80. Thomas J, Rigden DJ, Cronan JE: Acyl carrier protein phosphodiesterase (AcpH) of Escherichia coli is a non-canonical member of the HD phosphatase/phosphodiesterase family. Biochemistry; 2007 Jan 9;46(1):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acyl carrier protein phosphodiesterase (AcpH) of Escherichia coli is a non-canonical member of the HD phosphatase/phosphodiesterase family.
  • AcpH requires Mn2+ for activity, and thus, we focused on the metal binding ligands in order to locate the active site.
  • Bioinformatic investigations indicated that AcpH and its homologues were weakly related to a phosphodiesterase of known structure, the hydrolyase domain of the bifunctional bacterial protein, SpoT, suggesting that AcpH is a member of the HD family of phosphatases/ phosphodiesterases despite lacking the characteristic histidine of the motif.
  • These were then tested by site-directed mutagenesis.
  • We conclude that AcpH is a member of the HD protein family despite the lack of the signature histidine residue.
  • [MeSH-minor] Amino Acid Sequence. Binding Sites. Histidine / chemistry. Histidine / metabolism. Ligands. Manganese / metabolism. Models, Molecular. Molecular Sequence Data. Mutagenesis, Site-Directed. Protein Structure, Tertiary. Sequence Alignment

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198382.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI15650
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Escherichia coli Proteins; 0 / Ligands; 42Z2K6ZL8P / Manganese; 4QD397987E / Histidine; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.14 / AcpH protein, E coli
  •  go-up   go-down


81. AIRTUM Working Group: Italian cancer figures, report 2009: Cancer trend (1998-2005). Epidemiol Prev; 2009 Jul-Oct;33(4-5 Suppl 1):1-168
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific chapters are devoted to long-term trends (1986-2005), differences among age-groups, and international comparisons.
  • Mortality significantly decreased in both sexes for stomach cancer, rectum cancer, liver cancer, and Hodgkin lymphoma.
  • Incidence for all cancers together (except non-melanoma skin cancers) increased among men (APC +0.3) and remained stable among women.
  • Cancer sites which showed increasing incidence were thyroid and melanoma in both sexes, colon, testis, soft tissue among men, and lung and Hodgkin lymphoma among women.
  • For several cancer sites incidence decreased, e.g., stomach and Kaposi sarcoma (men and women), upper aerodigestive tract, oesophagus, lung, urinary bladder, myeloma and leukaemia (men), gallbladder, cervix uteri and ovary (women).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124636.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, Müller-Hermelink K, Diehl V, German Hodgkin's Study Group: Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol; 2005 Aug 1;23(22):5052-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.
  • PURPOSE: With improved prognosis for patients with Hodgkin's lymphoma (HL), interest increasingly focuses on high-risk groups such as elderly patients.
  • We thus performed a retrospective analysis using the German Hodgkin's Study Group (GHSG) database to determine clinical risk factors, course of treatment, and outcome in elderly HL patients in comparison with younger adults.
  • RESULTS: Elderly patients more often had mixed cellularity subtype, "B" symptoms, elevated erythrocyte sedimentation rate, and poorer performance status.
  • Less frequently observed were nodular sclerosis subtype, large mediastinal mass, and bulky disease.
  • As a result, significantly fewer elderly patients received the intended full chemotherapy dose (75% v 91%).
  • The survival analysis showed a significantly poorer treatment outcome for elderly patients in terms of 5-year OS (65% v 90%), FFTF (60% v 80%), and HL-specific FFTF (73% v 82%).
  • CONCLUSION: Elderly patients have a poorer risk profile compared with younger HL patients and experience more severe treatment-associated toxicity.
  • Higher mortality during treatment as well as lower dose-intensity are the major factors explaining the poorer overall outcome of elderly HL patients.
  • [MeSH-major] Aging. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955904.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Chandra D, Ewton A, Baker K: Hodgkin's disease presenting with osseous involvement. Am J Hematol; 2006 Jul;81(7):550-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease presenting with osseous involvement.
  • [MeSH-major] Bone Neoplasms / pathology. Hodgkin Disease / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755566.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


84. van der Putten RF, te Velthuis H, Aarden LA, ten Cate H, Glatz JF, Hermens WT: High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation. Clin Chem Lab Med; 2005;43(12):1386-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue factor was also measured in three successive plasma samples from 43 patients with type 2 diabetes mellitus.

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309378.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 9035-58-9 / Thromboplastin
  •  go-up   go-down


85. Briazzhikova TS, Iurlova TI: [Content of ceruloplasmin and immunoglobulins of the main classes in the blood sera of patients with herpes virus infection]. Zh Mikrobiol Epidemiol Immunobiol; 2005 May-Jun;(3):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Content of ceruloplasmin and immunoglobulins of the main classes in the blood sera of patients with herpes virus infection].
  • In 35 patients with herpes virus infection (males and females aged 25 to 45 years) the content of ceruloplasmin and immunoglobulins of the main classes in the blood sera and the content of IgA in saliva at the stages of exacerbation and remission were evaluated.
  • For control, a group of 35 healthy donors of the same ages were used.
  • In patients with relapsing herpes virus infection even at the period of remission reliably higher levels of ceruloplasmin and immunoglobulins of the main classes were registered in comparison with those in the group of healthy donors.
  • This was indicative of the fact that constant antigenic load caused by virus persistence and, in our opinion, could be regarded as a sign of unfavorable prognosis.
  • At the periods of exacerbation a reliable increased level of secretory IgA was registered in a group of patients with rare relapses of herpes virus infection in comparison with a group of patients with frequent relapses, which showed that patients with rare relapses had a better immune response.
  • [MeSH-major] Ceruloplasmin / analysis. Herpes Simplex / immunology. Herpes Simplex / metabolism. Immunoglobulins / blood
  • [MeSH-minor] Adult. Biomarkers / analysis. Female. Humans. Immunoglobulin A / analysis. Male. Middle Aged. Recurrence. Saliva / immunology

  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028529.001).
  • [ISSN] 0372-9311
  • [Journal-full-title] Zhurnal mikrobiologii, epidemiologii, i immunobiologii
  • [ISO-abbreviation] Zh. Mikrobiol. Epidemiol. Immunobiol.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin A; 0 / Immunoglobulins; EC 1.16.3.1 / Ceruloplasmin
  •  go-up   go-down


86. Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri F, Mancuso P, De Chiara A, Pinto A, Casola S, Simeone A: Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. Am J Pathol; 2009 Dec;175(6):2609-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma.
  • Here, we investigated OTX1 and OTX2 expression in Non-Hodgkin Lymphoma (NHL) and multiple myeloma.
  • OTX1 expression was activated in 94% of diffuse large B-cell lymphomas, in all Burkitt lymphomas, and in 90% of high-grade follicular lymphomas.
  • OTX1 was undetectable in precursor-B lymphoblastic lymphoma, chronic lymphocytic leukemia, and in most marginal zone and mantle cell lymphomas and multiple myeloma.
  • [MeSH-major] B-Lymphocyte Subsets / metabolism. B-Lymphocytes / metabolism. Biomarkers, Tumor / analysis. Germinal Center / metabolism. Lymphoma, Non-Hodgkin / metabolism. Otx Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):151-8 [10712946.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3413-20 [11719382.001]
  • [Cites] Nat Immunol. 2002 Apr;3(4):323-8 [11919568.001]
  • [Cites] Curr Opin Genet Dev. 2002 Aug;12(4):409-15 [12100885.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Nat Neurosci. 2003 May;6(5):453-60 [12652306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10299-303 [12934017.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1862-8 [14615382.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Genomics. 1994 Jul 1;22(1):41-5 [7959790.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Development. 1998 Dec;125(24):5091-104 [9811592.001]
  • [Cites] Trends Neurosci. 1999 Mar;22(3):116-22 [10199636.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):703-7 [15705863.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6351-7 [16155019.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):176-86 [16462208.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):499-504 [16734728.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1675-90 [10557039.001]
  • (PMID = 19893048.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / OTX1 protein, human; 0 / OTX2 protein, human; 0 / Otx Transcription Factors
  • [Other-IDs] NLM/ PMC2789631
  •  go-up   go-down


87. Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O'Connor OA: Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol; 2006 Aug;134(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
  • Based on three phase II studies of bortezomib in patients with non-Hodgkin lymphoma (140 assessable patients), we identified 26 patients who developed a unique erythematous maculopapular rash during treatment, six of whom underwent cutaneous biopsy.
  • Punch biopsy in six patients revealed a perivascular lymphocytic infiltrate without evidence of lymphoma, consistent with a non-necrotising cutaneous vasculitis.
  • The odds ratio for response given the development of a rash was 4.6 (95% CI, 1.7-12.4, P = 0.001).
  • Unlike classic hypersensitivity type reactions, this vasculitic rash may not necessarily prompt cessation of drug.
  • In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients.
  • [MeSH-major] Boronic Acids / adverse effects. Drug Hypersensitivity. Lymphoma, Non-Hodgkin / drug therapy. Protease Inhibitors / adverse effects. Pyrazines / adverse effects. Skin Diseases, Vascular / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Vasculitis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882131.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA 09207; United States / NCI NIH HHS / CA / U01 CA 69913
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


88. Koutros S, Holford TR, Hahn T, Lantos PM, McCarthy PL Jr, Risch HA, Swede H: Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. Leuk Lymphoma; 2007 Feb;48(2):357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA.
  • Moderately increased incidence rates have been observed during the spring for leukemias and Hodgkin's disease but few studies have been conducted of non-Hodgkin's lymphoma (NHL).
  • B-cell origin subtype, but not T-cell/NK, was diagnosed more frequently in March.
  • Controlling for age, sex, geographical location, and diagnosis year, multivariate Poisson regression revealed peaks in both March and April (P < 0.0001).
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Seasons

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Feb;48(2):223-4 [17325879.001]
  • (PMID = 17325897.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67005; United States / NCI NIH HHS / CA / R25 CA47883
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


89. Ilegems M, Douet V, Meylan-Bettex M, Uyttewaal M, Brand L, Bowman JL, Stieger PA: Interplay of auxin, KANADI and Class III HD-ZIP transcription factors in vascular tissue formation. Development; 2010 Mar;137(6):975-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interplay of auxin, KANADI and Class III HD-ZIP transcription factors in vascular tissue formation.
  • Class III HD-ZIP and KANADI gene family members have complementary expression patterns in the vasculature and their gain-of-function and loss-of-function mutants have complementary vascular phenotypes.
  • We have analyzed the vasculature of plants that have altered expression levels of Class III HD-ZIP and KANADI transcription factors in provascular cells.
  • Removal of either KANADI or Class III HD-ZIP expression in procambium cells led to a wider distribution of auxin in internal tissues, to an excess of procambium cell recruitment and to increased cambium activity.
  • Ectopic expression of Class III HD-ZIP genes promoted xylem differentiation.
  • We propose that Class III HD-ZIP and KANADI transcription factors control cambium activity: KANADI proteins by acting on auxin transport, and Class III HD-ZIP proteins by promoting axial cell elongation and xylem differentiation.

  • COS Scholar Universe. author profiles.
  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179097.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Homeodomain Proteins; 0 / Indoleacetic Acids; 0 / KANADI protein, Arabidopsis; 0 / Plant Growth Regulators; 0 / Transcription Factors
  •  go-up   go-down


90. Alfarano C, Sartiani L, Nediani C, Mannucci E, Mugelli A, Cerbai E, Raimondi L: Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells). Br J Pharmacol; 2008 Mar;153(5):907-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells).
  • To determine whether angiotensin II increases insulin resistance in cardiomyocytes, we studied the effect of angiotensin II on basal and insulin-stimulated transport rate of energy substrates in immortalized cardiomyocytes (HL-1 cells).
  • EXPERIMENTAL APPROACH: Glucose and palmitic acid uptakes were measured using [(3)H]2-deoxy-D-glucose and [(14)C]palmitic acid, respectively, in cells exposed or not exposed to angiotensin II (100 nM), angiotensin II plus irbesartan or PD123319, type 1 and 2 receptor antagonists, or PD98059, an inhibitor of ERK1/2 activation.
  • Type 1 receptor levels were measured by western blot analysis.
  • KEY RESULTS: Basal uptakes of glucose and palmitic acid by HL-1 cells (0.37+/-0.07 and 7.31+/-0.22 pmol per 10(4)cells per min, respectively) were both stimulated by 100 nM insulin (+91 and +64%, respectively).
  • Our results suggest a further mechanism for the cardiovascular protection offered by the angiotensin II type 1 receptor blockers.
  • [MeSH-major] Angiotensin II / pharmacology. Insulin / metabolism. Insulin Resistance. Myocytes, Cardiac / metabolism. Receptor, Angiotensin, Type 1 / drug effects
  • [MeSH-minor] Angiotensin II Type 1 Receptor Blockers / pharmacology. Animals. Cell Line. Cell Survival / drug effects. Glucose / metabolism. Hypertrophy. Mice. Palmitic Acid / metabolism

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. PALMITIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41077-84 [15252015.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7085-92 [9054401.001]
  • [Cites] Cardiovasc Res. 1997 Apr;34(1):25-33 [9217869.001]
  • [Cites] J Cardiovasc Pharmacol. 1998 Apr;31(4):576-80 [9554807.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):9006-12 [10085148.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1733-4 [15541431.001]
  • [Cites] Endocrinology. 2005 May;146(5):2246-54 [15705782.001]
  • [Cites] J Hypertens. 2005 May;23(5):905-11 [15834271.001]
  • [Cites] FEBS Lett. 2005 Apr 25;579(11):2428-32 [15848183.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):291-9 [15921682.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2005 Sep;3(5):821-9 [16181027.001]
  • [Cites] Circ Res. 2005 Dec 9;97(12):1262-9 [16284182.001]
  • [Cites] Br J Pharmacol. 2006 Mar;147(5):486-95 [16415913.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jun;317(3):1002-11 [16525038.001]
  • [Cites] Metabolism. 2006 Aug;55(8):1067-75 [16839843.001]
  • [Cites] J Mol Cell Cardiol. 2006 Aug;41(2):265-74 [16806260.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Aug-Sep;67(2-3):73-8 [12324223.001]
  • [Cites] Diabetes. 2002 Oct;51(10):3113-9 [12351456.001]
  • [Cites] J Physiol. 2002 Nov 15;545(Pt 1):81-92 [12433951.001]
  • [Cites] Biochem Cell Biol. 2002;80(5):655-65 [12440705.001]
  • [Cites] Mol Cell Biochem. 2002 Oct;239(1-2):181-92 [12479584.001]
  • [Cites] Biochem Soc Trans. 2004 Feb;32(Pt 1):83-5 [14748718.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H823-9 [14766671.001]
  • [Cites] Pflugers Arch. 2004 Apr;448(1):1-15 [14872244.001]
  • [Cites] Diabetes. 2004 Jul;53(7):1927-33 [15220222.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):543-67 [15294881.001]
  • [Cites] Diabetes. 1984 Nov;33(11):1078-84 [6500187.001]
  • (PMID = 17982475.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP05093
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Insulin; 0 / Receptor, Angiotensin, Type 1; 11128-99-7 / Angiotensin II; 2V16EO95H1 / Palmitic Acid; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2267260
  •  go-up   go-down


91. Davis QG, Paulino AC, Miller R, Ting JY: Mantle fields in the era of dynamic multileaf collimation: field shaping and electronic tissue compensation. Med Dosim; 2006;31(3):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mantle field radiotherapy for Hodgkin's disease is complicated by significant dose gradient (up to 10-20%) across the large fields required.
  • Many different strategies of tissue compensation have been investigated, including custom physical compensators to provide better dose distributions.
  • We present a method using dynamic multileaf collimator (dMLC) fluence modulation to simultaneously shape the treatment field and give homogeneous dose at depth throughout the classic mantle field.
  • Five patients were treated for early-stage Hodgkin's disease with a conventional anterior-posterior-posterior-anterior (AP-PA) mantle field.
  • An AP-PA dynamic MLC beam-shaped and dose-compensated plan was created for each, and compared with the conventional blocked plan.
  • Nine dose points were calculated at midplane in each plan.
  • Chamber measurements were taken to confirm accurate dMLC delivery of the planned doses.
  • The mean dose per fraction, relative to a central axis dose of 1.8 Gy, was increased in the conventional plans compared with the dMLC plans in the right (R) neck, left (L) neck, R supraclavicular, L supraclavicular, and L axillary points.
  • Measurements showed excellent agreement between planned doses and delivered doses, with less than 2% in-field variation.
  • Dynamic MLC fluence modulation was used to effectively deliver a mantle field that is both shape- and electronically-dose-compensated with sliding window MLC.
  • Homogeneity was significantly improved throughout the treatment field, and measurements confirmed accurate dose delivery using this technique.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Dose-Response Relationship, Radiation. Humans. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905447.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Wörmke S, Mackowski S, Brotosudarmo TH, Jung C, Zumbusch A, Ehrl M, Scheer H, Hofmann E, Hiller RG, Bräuchle C: Monitoring fluorescence of individual chromophores in peridinin-chlorophyll-protein complex using single molecule spectroscopy. Biochim Biophys Acta; 2007 Jul;1767(7):956-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Single molecule spectroscopy experiments are reported for native peridinin-chlorophyll a-protein (PCP) complexes, and three reconstituted light-harvesting systems, where an N-terminal construct of native PCP from Amphidinium carterae has been reconstituted with chlorophyll (Chl) mixtures: with Chl a, with Chl b and with both Chl a and Chl b.
  • Using laser excitation into peridinin (Per) absorption band we take advantage of sub-picosecond energy transfer from Per to Chl that is order of magnitude faster than the Förster energy transfer between the Chl molecules to independently populate each Chl in the complex.
  • The results indicate that reconstituted PCP complexes contain only two Chl molecules, so that they are spectroscopically equivalent to monomers of native-trimeric-PCP and do not aggregate further.
  • Through removal of ensemble averaging we are able to observe for single reconstituted PCP complexes two clear steps in fluorescence intensity timetraces attributed to subsequent bleaching of the two Chl molecules.
  • Importantly, the bleaching of the first Chl affects neither the energy nor the intensity of the emission of the second one.
  • Since in strongly interacting systems Chl is a very efficient quencher of the fluorescence, this behavior implies that the two fluorescing Chls within a PCP monomer interact very weakly with each other which makes it possible to independently monitor the fluorescence of each individual chromophore in the complex.
  • We apply this property, which distinguishes PCP from other light-harvesting systems, to measure the distribution of the energy splitting between two chemically identical Chl a molecules contained in the PCP monomer that reaches 280 cm(-1).
  • Most PCP complexes reconstituted with both Chl a and Chl b show two emission lines, whose wavelengths correspond to the fluorescence of Chl a and Chl b.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572378.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Light-Harvesting Protein Complexes; 0 / Protozoan Proteins; 1406-65-1 / Chlorophyll; 33281-81-1 / peridinin; 36-88-4 / Carotenoids; 5712ZB110R / chlorophyll b; YF5Q9EJC8Y / chlorophyll a
  •  go-up   go-down


93. Mihailov G, Ganeva P, Vassileva N, Guenova M, Balacenko G, Toshkov S, Hodjadjik D: Secondary acute myeloid leukemia early after therapy for Hodgkin's disease--a case report. J BUON; 2007 Jul-Sep;12(3):403-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute myeloid leukemia early after therapy for Hodgkin's disease--a case report.
  • A case of acute myeloid leukemia (AML) after successful therapy for Hodgkin's disease (HD) is reported.
  • The patient was diagnosed with stage IIB HD at the age of 25.
  • Knowing that the prognosis of patients with secondary AML (sAML) after primary HD is poor we decided to perform autologous peripheral stem cells' transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / surgery. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / surgery
  • [MeSH-minor] Adult. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Hodgkin Disease / therapy. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918297.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


94. Podol'skiĭ PN, Datsenko PV, Pan'shin GA, Sotnikov VM, Mel'nik IuD, Ivashin AV, Bozhenko VK: [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. Vopr Onkol; 2009;55(4):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
  • A computer database was created to take care of a wide range of protocols for combined treatment of Hodgkin's disease stage I-IV (n=1,573).
  • Our approach might promote individualization of prognosis as far as cardiac complications involved in Hodgkin's lymphoma are concerned.
  • [MeSH-major] Heart / radiation effects. Heart Diseases / etiology. Hodgkin Disease / radiotherapy


95. Buyukpamukçu M, Varan A, Aydin B, Kale G, Akata D, Yalçin B, Akyuz C, Kutluk T: Renal involvement of non-Hodgkin's lymphoma and its prognostic effect in childhood. Nephron Clin Pract; 2005;100(3):c86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal involvement of non-Hodgkin's lymphoma and its prognostic effect in childhood.
  • OBJECTIVE: To evaluate renal involvement in childhood lymphoma and define its prognostic effects.
  • PATIENTS AND METHODS: One hundred and four patients with non-Hodgkin's lymphoma and renal involvement on admission to a single center between 1972 and 2003 were evaluated retrospectively.
  • The renal infiltration pattern was nodular in 62 patients (59.6%) and diffuse in 40 patients (38.5%).
  • CONCLUSION: Impaired renal function is a poor prognostic factor for non-Hodgkin's lymphoma.
  • [MeSH-major] Kidney / pathology. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824512.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Klabusay M, Lysák D, Hrabcáková V, Navrátil M, Coupek P, Mayer J: [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation]. Cas Lek Cesk; 2008;147(6):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
  • [Transliterated title] Vliv typu růstového faktoru na fenotyp subpopulací a kinetiku CD34+ bunek v periferní krvi a stepech periferních kmenových bunek pacientů s non-hodgkinskými lymfomy indikovaných k autologní transplantaci krvetvorby.
  • BACKGROUND: Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin's lymphoma.
  • Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation.
  • Statistically significant differences in expression of lineage-committed antigens between growth factors were found (CD3, CD5--T-lineage, CD56 NK-lineage, CD20 for B-lineage, p < 0.05), as well as for lineage non-specific antigens (CD38, p < 0.05 and CD54, p < 0.01).
  • [MeSH-major] Antigens, CD34 / analysis. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Interleukin-3 / pharmacology. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation. Recombinant Fusion Proteins / pharmacology

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724529.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interleukin-3; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 193700-51-5 / leridistim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


97. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A: Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun; 2006 Jan;27(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
  • OBJECTIVES: To assess the usefulness of [18F]fluorodeoxyglucose positron emission tomography in the detection of bone marrow involvement in malignant lymphoma, and its impact in clinical management.
  • METHODS: One hundred and six consecutive patients with a confirmed diagnosis of lymphoma, referred for staging or restaging of Hodgkin's lymphoma (n=18) or non-Hodgkin's lymphoma (n=88), were reviewed retrospectively.
  • The assessment of bone marrow involvement by lymphoma was confirmed by histology and/or progression of bone marrow lesions in clinical follow-up.
  • Ten cases of non-Hodgkin's lymphoma and two cases of Hodgkin's lymphoma with positive positron emission tomography results and an initial negative bone marrow biopsy showed clinical progression of the bone marrow lesions and/or subsequent positive histology.
  • In seven of the 12 positive cases with negative bone marrow biopsy, positron emission tomography uptake distant from the site of the biopsy was seen.
  • In four cases of follicular lymphoma, the bone marrow biopsy was positive and the positron emission tomography scan was normal.
  • CONCLUSIONS: Positron emission tomography and bone marrow biopsy are complementary in assessing the presence of bone marrow involvement in patients with malignant lymphoma.
  • In our series, positron emission tomography was more sensitive than bone marrow biopsy in Hodgkin's and non-Hodgkin's lymphoma, except in follicular lymphoma.
  • [MeSH-major] Biopsy, Needle / methods. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18. Ilium / pathology. Lymphoma / pathology. Lymphoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340718.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • The mean follow-up time for chemotherapy was 40 months (range 20-110 months) with an average dose of prednisone of 8.45 g (range 3.20 - 18.50).
  • The clinical outcomes (time to postoperative pain, time to radiological failure, and time to arthroplasty from the forage) following surgical management using the forage-biopsy technique with and without internal electrostimulation (IES) were recorded.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


99. Kornblit B, Masmas T, Madsen HO, Ryder LP, Svejgaard A, Jakobsen B, Sengeløv H, Olesen G, Heilmann C, Dickmeiss E, Petersen SL, Vindeløv L: Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant; 2008 May;41(10):851-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
  • We analysed the outcome and hospitalization requirements of the first 100 patients (Hodgkin's disease (HD), N=13; multiple myeloma (MM), N=14; CLL, N=12; non-Hodgkin's lymphoma (NHL), N=17; myelodysplastic syndrome (MDS), N=18; AML, N=24 and CML, N=2) treated in Denmark with haematopoietic cell transplantation after non-myeloablative conditioning with TBI 2 Gy+/-fludarabine.
  • Patients with MM, HD and MDS and a history of > or =5% blasts had a less favourable outcome with a PFS of 19-38% (P=0.001).
  • [MeSH-minor] Adult. Aged. Denmark / epidemiology. Female. Graft vs Host Disease / epidemiology. Hodgkin Disease / therapy. Hospitalization / statistics & numerical data. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / therapy. Myelodysplastic Syndromes / therapy. Outpatient Clinics, Hospital / utilization. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246114.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


100. Chan K, Behling E, Strayer DS, Kocher WS, Dessain SK: Prolonged hemophagocytic lymphohistiocytosis syndrome as an initial presentation of Hodgkin lymphoma: a case report. J Med Case Rep; 2008;2:367
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged hemophagocytic lymphohistiocytosis syndrome as an initial presentation of Hodgkin lymphoma: a case report.
  • She was found to have stage IV classical Hodgkin lymphoma, in addition to Epstein-Barr virus and cytomegalovirus viremia.
  • CONCLUSION: Fulminant hemophagocytic lymphohistiocytosis may follow a prodromal phase that possesses features suggestive of a chronic form of hemophagocytic lymphohistiocytosis, but which may also resemble immune cytopenias of other causes.
  • A diagnosis of hemophagocytic lymphohistiocytosis should be considered in the setting of chronic pancytopenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1992 Feb;9(1):63-74 [1561489.001]
  • [Cites] Ann Intern Med. 1979 Jul;91(1):60-1 [464459.001]
  • [Cites] Ann Hematol. 2003 Jan;82(1):53-6 [12574967.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2367-73 [12239144.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3259-64 [8241498.001]
  • [Cites] Ann Hematol. 1993 Jul;67(1):49-56 [8334200.001]
  • [Cites] Am J Hematol. 1997 May;55(1):49-50 [9136919.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):560-5 [9690550.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1648-51 [15466922.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:82-8 [16304363.001]
  • [Cites] Clin Infect Dis. 2008 Aug 15;47(4):531-4 [18611160.001]
  • [Cites] Emerg Infect Dis. 2000 Nov-Dec;6(6):601-8 [11076718.001]
  • [Cites] Ann Hematol. 2000 Jun;79(6):322-6 [10901612.001]
  • (PMID = 19055804.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2613409
  •  go-up   go-down






Advertisement